Prerpints.org logo
Preprint
Review

What Do We Know about the Relationship between Lycopene and Metabolic Diseases? Review

Altmetrics

Downloads

90

Views

54

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

24 September 2024

Posted:

26 September 2024

You are already at the latest version

Alerts
Abstract
Metabolic syndrome, obesity, and type 2 diabetes are closely related. They are characterized by chronic inflammation and oxidative stress. Obesity is the most important risk factor for metabolic syndrome and type 2 diabetes. Metabolic syndrome is characterized by insulin resistance and elevated blood glucose levels, among other conditions. These disorders contribute to the development of type 2 diabetes, which can exacerbate other metabolic disorders. Numerous studies indicate that diet and nutrients can have a major impact on preventing and treating these conditions. One such ingredient is lycopene. It exhibits antioxidant and anti-inflammatory effects and can affect metabolic processes in the body. According to the research presented, lycopene supplementation may have significant potential in the prevention and treatment of metabolic syndrome, obesity, and type 2 diabetes.
Keywords: 
Subject: Medicine and Pharmacology  -   Pharmacy
1. Introduction
The development of metabolic illnesses is mainly caused by oxidative stress and chronic inflammatory conditions [1,2]. They play an important role in the development of co-occurring metabolic diseases such as increased glucose intolerance, high blood pressure, and hyperlipidemia, which lead to metabolic dysfunction [3].
Inflammation promotes metabolic disorders, making it a key target for preventing and treating these widespread diseases. Identifying nutritional strategies that reduce inflammation is a promising approach to limit the impact of metabolic diseases [4,5].
Oxidative stress is also associated with metabolic diseases. Oxidative stress can cause and result from obesity [6]. Consumption of fats, carbohydrates, and saturated fatty acids - especially trans-fatty acids—in excess triggers specific internal processes that result in the production of superoxide through oxidative phosphorylation, glyceraldehyde autoxidation, protein kinase C activation, and the activation of the polyol and hexosamine pathways [6,7,8].
Obesity may cause oxidative stress in the body. The causes are chronic inflammation, inadequate antioxidant defenses, hyperleptinemia, aberrant postprandial metabolism, reactive oxygen species (ROS) production, elevated nitrogen oxides (NOX) activity, and endoplasmic reticulum stress [6,8,9]. Obesity is also associated with inflammation. Tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) are inflammatory cytokines that are released from the adipocytes of obese individuals. These pro-inflammatory transcription factors, such as nuclear factor-kappa B (NF-κB) and activator protein-1 (AP-1), are redox-sensitive and create a vicious cycle by increasing ROS production [7,10,11].
Obesity and metabolic syndrome are closely related. Obesity increases the risk of inflammation and oxidative stress, which in turn raises the risk of several disorders involving the elements of the metabolic syndrome: hypertension, insulin resistance, and hyperlipidemia [3].
One of the main contributors to the development of insulin resistance and metabolic syndrome is central obesity [12]. Low-grade inflammation linked to obesity can potentially cause insulin shortage, insulin resistance, and metabolic problems [2]. In response to elevated blood glucose, pancreatic β cells release insulin. It increases glucose absorption in the liver, muscles, and adipose tissues while inhibiting lipolysis and hepatic gluconeogenesis [13]. People with metabolic syndrome often have the problem of insulin resistance - with normal plasma insulin levels, the target tissues cannot respond effectively to lower glucose levels [14]. Insulin resistance impairs glucose metabolism, leading to β cell hypertrophy, increased insulin production, and hyperinsulinemia [14,15]. Insulin resistance can cause endothelial dysfunction, visceral obesity, hyperglycemia, hypertension, dyslipidemia, inflammation, thrombosis, and hyperglycemia. Through several intricate processes, these conditions can result in type 2 diabetes mellitus (T2DM), metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD) [3,15,16].
Adipose tissue and the liver are the primary locations of carotenoid accumulation [17,18]. Due to its lipophilic nature, lycopene is found in greater concentration in adipose tissue than in serum [19]. This tissue metabolism can be influenced by carotenoids and their metabolites [20]. Obesity has been linked to low blood concentrations of carotenoids and nutritional deficits in carotenoids [21,22].
The most prevalent carotenoid in the human body is lycopene. It makes up almost half of the overall carotenoid content [23]. Lycopene is not synthesized by the human body. It must be supplied with the diet [24]. Tomatoes and tomato-based products are the most common sources of this component in the human diet [25].
Lycopene has an antioxidant activity. It removes singlet oxygen with the greatest efficiency from all carotenoids [26]. Twice as much as beta-carotene and ten times more than α-tocopherol, lycopene may quench singlet oxygen [27]. It may remove hydrogen peroxide, nitrogen dioxide, hydroxyl radicals, singlet oxygen, and ROS [28,29]. It affects reactive oxygen species by electron transfer, radical attachment, and allylic hydrogen abstraction [28]. Free radicals and lycopene can interact in a variety of ways [28,30]. Additionally, it raises the concentrations of enzyme antioxidants such as glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT). This results from the activation of the nuclear factor E2 (NFE2L2), an associated antioxidant response element [31]. Furthermore, non-enzymatic antioxidants like vitamins C and E can be renewed by lycopene—the cellular antioxidant defense system benefits from this [29]. Because of its antioxidant qualities, lycopene can shield crucial bodily components like DNA and lipids [32].
Lycopene has an anti-inflammatory effect. Many studies in animal models and humans indicate its beneficial effects in preventing and combating inflammation in metabolic diseases [33]. It affects the regulation of signaling pathways involving the formation of inflammatory mediators [34]. It reduces pro-inflammatory cytokines: IL-6, IL-1β, and TNF-α [35,36]. It reduces the expression of pro-inflammatory mediators cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS). It reduces also nitric oxide (NO) production [37]. Through its antioxidant activity, lycopene inhibits the expression of nuclear factor kappa B (NF-κB). Thus, it inhibits the formation of pro-inflammatory cytokines [38,39]. Lycopene may also decrease inflammation by reducing oxidative stress [40].
The biological action of lycopene is broad. Numerous studies demonstrate the protective benefits of lycopene-containing tomato-based products and lycopene against various chronic illnesses [41,42].
Chronic inflammation and oxidative stress are linked to several illnesses. Researchers are curious about the potential health benefits of lycopene as an agent that mitigates various ailments connected with metabolic diseases. This review aims to provide the findings from studies on lycopene's impact on metabolic syndrome, obesity, and type 2 diabetes mellitus.

2. Metabolic syndrome

Metabolic syndrome (MetS) is not a disease in itself. It is a term used to describe a collection of metabolic risk factors such as abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low high-density lipoprotein cholesterol [43]. The presence of metabolic syndrome is associated with an increased risk of developing cardiovascular disease and diabetes [13]. Compared to individuals without the syndrome, those with MetS have a 2-fold increased risk of developing cardiovascular disease within the next five to ten years, a 5-fold increased risk of type 2 diabetes mellitus, a 2-4-fold increased risk of stroke, a 3-4-fold increased risk of myocardial infarction, and a 2-fold increased risk of dying [44]. Globally, the metabolic syndrome is a significant public health issue [45]. According to estimates, the prevalence of MetS varies between <10% and up to 84% worldwide, depending on the area, age, sex, race, and ethnicity studied, as well as the criteria used to categorize patients. As a result, it is thought that 25% of adult people worldwide suffer from MetS [44].
There are many definitions of MetS, but the one most frequently used to evaluate this condition is the National Cholesterol Education Program's Adult Treatment Panel III (ATP III) report [46]. According to this definition, MetS is diagnosed by the presence of three or more of the following factors: blood glucose > 5.6 mmol/L (100 mg/dl) or drug treatment for hyperglycemia, high-density lipoprotein (HDL) < 1.0 mmol/L (40 mg/dl) in men, < 1.3 mmol/L (50 mg/dl) in women or treatment for low HDL, triglycerides > 1.7 mmol/L (150 mg/dl) or treatment for hypertriglyceridemia, waist circumference > 102 cm in men or > 88 cm in women, blood pressure > 130/85 mmHg or treatment for hypertension [47].
The pathogenesis of metabolic syndrome is complex [48]. Factors contributing to the development of metabolic syndrome include genetic and epigenetic factors and environmental factors such as lifestyle, physical inactivity, and overeating. High-calorie intake is one important cause, as it can cause visceral obesity, which is a factor that activates most of the pathways involved in metabolic syndrome [49,50,51]. Obesity changes the secretory activity of the fatty tissues, which favors the emergence of prediabetes, insulin resistance, and other metabolic disorders [52].
One of the most critical factors contributing to this syndrome is chronic inflammation occurring systemically [13]. Several current researches indicate a connection between inflammation and MetS. Slagter et al. [53] provided evidence about the adverse effects of obesity on quality of life, demonstrating that the degree of obesity, MetS, T2DM, and inflammation improves the quality of life and that these factors are mostly linked to worse physical health [53]. Higher body mass index (BMI) was linked to lower levels of inflammation in MetS people, as well as insulin resistance and higher atherogenic dyslipidemia. A positive correlation between BMI, IL-6, and pro-inflammatory C-reactive protein (CRP) supported this thesis [54]. Marques-Rocha et al. [55] demonstrated that an 8-week intervention using a Mediterranean diet altered the expression of miR-155-3p and let-7b in white blood cells in individuals with MetS. The Mediterranean diet significantly impacted the expression of microRNAs (miRNAs) linked to inflammation. The control of inflammatory genes has been linked to the production of these miRNAs, but they have also been shown to play a role in the development of human metabolic diseases [55].
Numerous studies have found that patients with metabolic syndrome had reduced plasma antioxidant enzyme activity and higher levels of oxidative stress biomarkers compared to healthy people [3].
Lifestyle changes and reduced exposure to risk factors are recommended for people at risk of developing this condition [48]. Research has confirmed that engaging in physical activity and calorie restriction contribute to reducing the risk factors for metabolic syndrome [56,57,58]. A critical factor in the development and treatment of the disease is diet. Dietary products directly impact the body's metabolic functions, including blood pressure, cholesterol, glucose metabolism, and distribution of body fat [59]. Studies have demonstrated the potential benefits of some nutraceuticals in the management of metabolic syndrome [48]. One such ingredient is lycopene. Many studies indicate its beneficial effects in preventing and treating metabolic syndrome.
Albrahim et al. [60] conducted the study on male Wistar rats showing that lycopene helped prevent issues associated with obesity. It stopped weight growth and increased liver weight by reducing blood cholesterol, apolipoprotein B (Apo-B), triglycerides (TG), and LDL and raising serum HDL levels. It also lowered glucose and insulin levels and lipid metabolism by raising hepatic peroxisome proliferator-activated receptor gamma (PPAR-γ) levels. Lycopene also prevented obesity-induced oxidative stress, inflammation, and fibrosis in the liver. This activity was caused by raised levels of antioxidant enzymes (SOD, CAT, glutathione (GSH), GPx, and glutathione reductase (GR)), lowered malondialdehyde (MDA) and NO levels, suppressed inflammatory markers (IL-1β, TNF-α, and myeloperoxidase (MPO)), and decreased fibrosis markers (alpha-smooth muscle actin (α-SMA) and transforming growth factor-beta 1 (TGF-β1)) in the liver. Additionally, by reducing blood levels of creatine kinase, lactate dehydrogenase (LDH), and atherogenic index, lycopene reduced obesity-induced cardiac problems [60]. Fenni et al. [61] conducted a study that assessed the effect of lycopene and tomato powder supplementation on obesity-induced inflammation in C57BL/J6 mice. The consumption of the tested ingredients led to a decrease in adipocyte hypertrophy and expression of the PPAR-γ gene considered a key regulator of adipogenesis. It explains the reduction in obesity in mice that received lycopene and tomato powder. Furthermore, the transcription factors SREBP-1c and FAS gene levels were decreased. The researchers observed a reduction in proinflammatory cytokines (TNF-α, IL-6) and chemokines (CCL2 and CCL5). It might be linked to a decline in the phosphorylation of two crucial NF-kB signaling components, IkB and p65. The results suggest that the ability of lycopene and tomato powder to block NF-κB signaling in adipose tissue accounts for their anti-inflammatory effects on this tissue [61]. Ugwor et al. [62] investigated the effect of lycopene on obesity-induced cardiometabolic changes in female albino rats. A Western-style diet was used to induce obesity. Lycopene treatment decreased lipid concentrations and restored lipid and lipoprotein metabolism. The carotenoid increased nitric oxide levels and IL-10 messenger RNA transcripts and inhibited the production of mediators that promote inflammation (NF-κB-p65, IL-1β, and IL-6). Lycopene also reduces the cardio-pathological harm caused by obesity [62].
There are also human studies showing the effect of lycopene on metabolic syndrome. Table 1 shows the human studies reported in this article. Yeo et al. [63] investigated whether there was an association between arterial stiffness, antioxidant levels (lycopene, β-carotene, α-tocopherol), and MetS risk. Lycopene concentrations fell as the number of risk factors for MetS rose. Serum lycopene concentrations and risk variables (waist circumference, blood pressure, triglyceride, fasting glucose, and HOMA-IR) were found to be inversely correlated. Only waist circumference, triglyceride, and HOMA-IR showed significant relationships once covariates were taken into account. The investigation results indicated a connection between MetS, brachial-ankle pulse wave velocity, and circulating lycopene. A significant rise in brachial-ankle pulse wave velocity in MetS may be linked to decreased lycopene levels [63]. Liu et al. [64] investigated the relationship between serum carotenoid concentrations (lycopene, α-carotene, β-carotene, β-cryptoxanthin, and lutein/zeaxanthin) and the prevalence of MetS in Chinese people. The prevalence of MetS in the subjects studied was estimated at 11.4%. People with MetS, compared to those without the syndrome, had increased waist circumference, BMI, blood pressure, fasting blood glucose and triglycerides, and lower HDL-C concentrations. Participants without MetS had higher α-tocopherol and retinol concentrations than those without the syndrome. The study showed an inverse relationship between serum carotenoid concentrations and the incidence of MetS [64]. Han et al. [65] investigated how BMI affects the association between serum lycopene concentrations and metabolic syndrome. Participants with the lowest lycopene concentrations had a higher incidence of MetS than participants in the other groups with higher lycopene concentrations. The study confirmed that BMI influenced the association between serum lycopene concentrations and the incidence of metabolic syndrome. However, this association was only significant in patients who were normal-weight and overweight. In obese subjects, this relationship was not confirmed [65]. Choi and Ainsworth [66] evaluated the relationship between MetS risk, food intake and, serum vitamins and antioxidants levels, and physical activity in adults. The study showed that translycopene concentrations were positively related to the daily number of steps. The group with the lowest number of steps had the lowest serum lycopene levels, while the most active group had the highest. People with sedentary lifestyles had a higher risk of developing MetS than those who were active. The study's findings suggest that a decreased chance of developing MetS and an increased amount of steps are linked to elevated blood levels of carotenoids, especially lycopene. However, it should be noted that moderately and highly active people consumed a higher amount of high-value foods than inactive people [66]. Han et al. [67] conducted a study to determine whether lycopene is related to mortality among people with MetS. People with the highest lycopene concentrations had longer mean survival times than those with the lowest serum concentrations of this carotenoid. The results of the study imply that among people with metabolic syndrome, serum lycopene concentrations are linked to a lower risk of death [67]. Bouayed et al. [68] conducted a study to investigate the association between carotenoid intake and metabolic syndrome. The study included 1,346 participants. 27.1% of the individuals had metabolic syndrome. Carotenoid intake was determined by linking findings, primarily using United States Department of Agriculture (USDA) food databases. Intake of carotenoids varied in their impact on metabolic state, risk, and syndrome, as well as the cardiometabolic components of it. Lycopene showed a somewhat favorable correlation with MetS scores and its constituent parts. Even enough, these negative effects vanished for lycopene when consumption of tomato-based convenience meals was taken into account, suggesting a rather unhealthy and westernized diet [68]. Tsitsimpikou et al. [69] investigated how people with metabolic syndrome's risk status were affected by supplementing with tomato juice. The study did not state the precise amount of tomato juice, but it did state that an average of 2.51 mg of lycopene was present in 100 g of tomato drink. There was a rise in HDL cholesterol and a decrease in LDL cholesterol. Furthermore, a noteworthy reduction in the fasting insulin resistance score was noted within the therapy group. Patients who took tomato juice supplementation showed a marked reduction in inflammation and endothelial dysfunction. The study's findings indicate tomato juice's potential moderating influence on risk variables linked to metabolic syndrome. The absence of a defined quantity of tomato juice and its lycopene concentration is one of the study's limitations [69]. Li et al. [70] investigated how supplementing with tomato juice affected adipokine profiles and metabolic health-related indicators in people who were otherwise in good health. Supplementing with tomato juice significantly lowered blood levels of cholesterol, thiobarbituric reactive chemicals, monocyte chemoattractant protein-1 (MCP-1), body weight, body fat, waist circumference, and BMI. Triglycerides, lycopene, and adiponectin increased in the serum at the same time. To be sure that these findings weren't impacted by notable drops in body weight, BMI, or body fat, a subanalysis was done. The results for the MetS variables remained significant even after splitting the subjects into responders (fat decrease) and non-responders (no fat loss). The findings indicate that in young, healthy women, taking tomato juice supplementation on a regular basis lowers waist circumference, serum cholesterol, and inflammatory adipokine levels. Body fat variations have no bearing on these outcomes. The lack of a control group in the trial was due to the authors' observation that creating a realistic placebo drink would be impossible. Furthermore, the fact that only women of normal weight took part in the study may have hampered the credibility of the findings [70]. Mirahmadi et al. [71] conducted a randomized, double-blind, objective clinical trial to examine the effects of lycopene on oxidative stress, inflammatory markers, and liver enzymes in individuals with metabolic syndrome. Lycopene reduced C-reactive protein (CRP) and prooxidant-antioxidant balance (PAB) levels. No differences were observed in alanine aminotransferase (ALT), aspartate transferase (AST), and alkaline phosphatase (ALP) levels [71].
Numerous studies in animal models and human populations provide evidence for the beneficial effects of lycopene on metabolic syndrome. Animal studies have shown that lycopene can alleviate symptoms such as dyslipidemia, inflammation, oxidative stress, and metabolic disorders. In humans, cross-sectional studies suggest that higher blood lycopene levels are associated with a lower risk of metabolic syndrome and its components, such as insulin resistance, abdominal obesity, and elevated blood pressure. Interventional studies in humans confirm that lycopene supplementation can improve lipid profiles, reduce inflammation, and support metabolic functions. However, not all studies are consistent with all parameters. Differences in the obtained results may be caused by various methodological limitations. In summary, lycopene shows potential as a natural agent supporting the prevention and treatment of metabolic syndrome. However, further clinical studies are needed to confirm its activity in this condition.

3. Obesity

The excessive build-up of fat throughout the body or in specific organs is defined as obesity [72]. A person is considered obese if their body mass index (BMI), which is calculated by dividing their weight by the square of their height, is more than or equal to 30. Overweight people have a BMI between 25 and 29.9 [73]. It is a chronic, progressive, recurring illness that harms both metabolic and psychological well-being [72]. There is a correlation between a number of risk factors and the elevated risk of obesity, including diets, gut microbiota, aging, genetics, and environmental variables [74]. An imbalance between the body's stored extra energy and its used energy is one of the primary causes of obesity. This situation can interfere with food signals and lead to inadequate energy expenditure [75].
One of the main characteristics of obesity and the comorbidities that go along with it is thought to be chronic low-grade or metabolic inflammation [76,77,78]. Chronic low-grade inflammation is associated with impaired production of cytokines, acute-phase proteins, chemokines, miRNA, and other immune response mediators, as well as with the induction of inflammatory signaling pathways [76,79,80,81,82,83]. An important factor in preserving this condition is adipose tissue [84].
Inflammation of adipose tissue in obese people can be facilitated by immune cells, particularly macrophages. These cells in adipose tissue play a key role in energy metabolism: pro-inflammatory (M1) macrophages promote hepatic steatosis and adipogenesis, while anti-inflammatory (M2) macrophages have the opposite effect [85]. Pro-inflammatory reactions and pro-inflammatory-related factors, including IL-6, IL-12, and TNF-α, are produced by M1 macrophages [86]. M2 macrophages secrete cytokines that inhibit inflammation, including vascular endothelial growth factor (VEGF), IL-10, and arginase-1 (Arg-1) [87]. Reduced inflammation originating from adipose tissue in obesity may be achieved by changing the polarization of adipose tissue macrophages from M1 to M2 macrophages [85,88].
Obesity has a major negative influence on both physical and mental health. It raises the risk of several chronic conditions, such as diabetes, dyslipidemia, cardiovascular disease, osteoarthritis, and hypertension [89]. Obesity-related diseases are also associated with greater levels of oxidative stress, which might be the cause of additional issues connected to metabolic syndrome [90]. Obesity is a significant factor contributing to the occurrence of this syndrome [91].
Epidemiological research and preclinical trials indicate that lycopene may be helpful in the treatment of obesity [92]. Studies have shown that lycopene has anti-inflammatory effects in adipose tissue [93,94]. Many studies in animal models and humans indicate its beneficial effects in preventing and fighting obesity.
Lycopene showed antioxidant and anti-inflammatory activity in male Sprague-Dawley rats with nonalcoholic steatohepatitis fed a high-fat diet. The tested carotenoid reduced the levels of TNF-α and MDA in serum and increased the concentration of GSH in the liver. It also improved tissue insulin resistance. Alanine aminotransferase (ALT) and triglyceride levels decreased. Hepatic steatosis and inflammation in the liver decreased under the influence of the tested carotenoid. A reduction in serum TNF-α levels was also observed. The expression of α-smooth muscle actin (α-SMA) and cytochrome P450 2E1 (CYP 2E1) decreased in rats fed lycopene. There was no significant difference between the different doses of lycopene and the effects obtained [95]. In C57BL/6J mice fed a high-fat diet, lycopene attenuated glucose intolerance and hyperinsulinemia. The researchers also observed reduced adipocyte hyperplasia and macrophage infiltration in the epididymal white adipose tissue, as well as inflammation and hepatic steatosis. The carotenoid reduced the amount of adipose tissue macrophages and also had an effect on M1 and M2 polarization - M2 predominance over M1 was observed in the studied macrophages. In adipose tissue macrophage, lycopene promotes dominant M2 polarization. This process reduces inflammation and insulin resistance in the liver and epididymal white adipose tissue caused by a high-fat diet [96]. In a 12-week trial, lycopene decreased obesity and weight gain in Swiss white mice given a high-fat diet. It reduced systemic obesity and total serum triglycerides, improved hepatic glucose and lipid metabolism, and accelerated glucose clearance and insulin sensitivity. All of these actions contributed to improving adipose tissue mobilization and reducing insulin resistance [97]. Kim et al. [98] showed that lycopene added to tomato wine inhibited body weight growth in male Sprague-Dawley rats fed a high-fat diet without lowering food consumption. Another study in C57BL/6J mice showed that lycopene supplementation prevented the development of obesity. Lycopene reduced fat storage in adipose tissue and supported lipid metabolism by blocking the expression of genes responsible for lipogenesis (Acaca, Fas, Pparγ, Srebp1c, and Pparg) and activating genes related to lipidolysis and thermogenesis (Pgc1α, Prdm16, Ucps, and Ebf2), as well as mitochondrial function (Sirt1, Cox5b, Cox8b, CoxII, and Cycs). Lycopene also inhibited autophagy-dependent lipid accumulation by reducing the expression of autophagy-related genes (Atg7, Atg14, Lc3, P62, and Beclin). Additionally, it improved insulin sensitivity by reducing leptin levels and increasing the expression of glucose transporters Glut1 and Glut4. Lycopene also reduced inflammation and intestinal leakiness by reducing the expression of inflammatory biomarkers (IL-1β, IL-6, iNOS, TNF-α, and Cox-2) and enhancing the expression of proteins responsible for intestinal barrier integrity, such as Zo-1, claudin-1, and occludin [99]. Zeng et al. [100] found that lycopene significantly prevented insulin resistance in mice fed a high-fat diet. It lowered blood glucose and insulin levels, improved glucose and insulin tolerance, and increased liver glycogen content. Lycopene also reduced inflammation by inhibiting the increase in IL-1β, TNF-α, and CRP levels. It improved lipid profiles by reducing total cholesterol, triglycerides, and LDL levels and increasing HDL levels. Additionally, lycopene inhibited STAT3 expression and phosphorylation in the liver and blocked STAT3 signaling and Srebp-1c gene expression, which prevented inflammation, lipid accumulation, and metabolic dysfunction [100]. Lorenz et al. [101] found that lycopene administered to male New Zealand White rabbits fed a high-cholesterol diet reduced serum total cholesterol and LDL cholesterol levels and also reduced aortic cholesterol ester levels [101]. Researchers administered lycopene to male Wistar rats on a hyperenergetic diet to examine its effects on adipokine expression in obesity. Supplementing with lycopene significantly lowered plasma levels of resistin, leptin, and IL-6 gene expression in epididymal adipose tissue, but it had no effect on body weight or adiposity. The expression of the MCP-1 gene in epididymal adipose tissue was likewise markedly decreased. According to the study, lycopene might be a useful tactic for lowering inflammation in obesity [102]. Luvizotto et al. [103], in a study on male Wistar rats, fed a hypercaloric diet, observed that lycopene, through its effect on adipose tissue, may play a role in preventing complications associated with obesity. After administration of the carotenoid to rats, they observed an increase in its concentration in plasma and in the expression of adiponectin mRNA in adipose tissue. In fat cells of obese rats, lycopene treatment also enhanced the expression of SIRT1, FoxO1, and FAT/CD36 mRNA but lowered the expression of PPARγ [103].
However, some researchers found that administering lycopene to obese animals did not impact body weight or adiposity index [102,103,104,105]. This inconsistency might be due to animal models, a form of lycopene and its carrier, variations in dosage, and treatment duration.
There are also human studies on the effects of lycopene on obesity. These trials are summarized in Table 2. In a cross-sectional study, Harari et al. [106] discovered a negative correlation between blood levels of CRP, waist circumference, body fat, and BMI, and the concentration of lycopene in the blood. Han et al. [107] found that higher blood uric acid levels were associated with hypertension in adults with BMI ≥ 25. Blood lycopene levels were inversely associated with hypertension. Additionally, the lycopene to uric acid ratio was significantly associated with hypertension in overweight and obese individuals [107]. McMorrow et al. [108] discovered that a dietary supplement including, among others, lycopene preserved high molecular weight adiponectin levels and decreased insulin resistance as measured by homeostatic model analysis (HOMA-IR) in a randomized, controlled crossover trial of overweight teenagers. This resulted from the methylation of adipogenic genes being modulated in both directions [108]. Negri et al. [109] conducted a randomized cross-over clinical trial, to examine the effect of lycopene-rich tomato juice in obese children. Tomato juice supplementation enhanced lipid and glucose metabolism. This was linked to the reduction of inflammation and oxidative stress as well as to its impact on T lymphocyte mitochondrial metabolic control [109]. Park et al. [110] showed in their study that serum lycopene levels are negatively correlated with BMI in overweight children aged 9-10. Ghavipour et al. [111] investigated the effect of tomato juice consumption on markers of oxidative stress in overweight and obese women. In overweight individuals, after 20 days of tomato juice intake, the researchers observed significant increases in plasma total antioxidant capacity (TAC), erythrocyte SOD, GPx, and CAT. They also observed decreases in serum MDA. However, in the obese group, these changes were not statistically significant [111].
Wiese et al. [112] in a randomized, double-blind, 1-month study, examined the effects of lycopene on middle-aged adults with moderate obesity (BMI between 30 and 35). Supplementing with lycopene enhanced the relative number of lactobacilli, bifidobacteria, and other beneficial gut microorganisms. Improvements in skeletal muscle oxygenation and hepatic lipid metabolism were noted by the researchers. Additionally, they observed a decrease in skin corneocyte desquamation and an increase in skin sebum viscosity. This study demonstrated the prebiotic potential of lycopene [112].
On the other hand, Ben Amara et al. [113] conducted a cross-sectional observational research with 108 obese, non-diabetic participants and found no correlation between plasma lycopene levels and BMI, adipokines, or insulin resistance. Their inability to account for dietary composition using a validated eating pattern questionnaire, however, could have compromised their capacity to estimate carotenoid consumption precisely. Furthermore, the study's limited sample size, imprecise definition of obesity, and absence of an age- and sex-matched control group could have compromised the lycopene's reported therapeutic advantages [113].
Numerous studies in animal models and humans have shown that lycopene may have a beneficial effect on the treatment of obesity and metabolic disorders associated with it. In animal studies, lycopene supplementation led to reduced inflammation, improved insulin sensitivity, and reduced fatty liver disease in rodents fed a high-fat diet. Reduced levels of inflammatory markers such as IL-6 and TNF-α, and improved glucose and lipid metabolism were also observed. However, not all studies have shown the effect of lycopene on body weight and obesity indicators. This may be due to differences in animal models, lycopene formulation, doses, and duration of therapy.
Human studies have confirmed the association between higher blood lycopene levels and better health indicators, including lower BMI, waist circumference, and CRP levels. Lycopene supplementation in overweight and obese individuals led to improved lipid and glucose metabolism, reduced oxidative stress, and improved insulin sensitivity. Lycopene has also been shown to have a prebiotic potential, with beneficial effects on gut microbiota composition and metabolism.
However, some studies have not confirmed a significant association between lycopene levels and obesity indicators. This may be due to methodological limitations, such as small sample sizes, imprecise assessment of carotenoid intake, and lack of appropriate control groups. Overall, lycopene shows promising properties in the prevention and treatment of obesity, but further studies are needed to confirm its effects.

4. Type 2 Diabetes Mellitus

Diabetes is a chronic illness that ranks among the world's most serious issues with public health [114,115].
Insulin resistance, decreased insulin production, or a combination of the two can lead to type 2 diabetes. High blood glucose levels are the outcome of insulin resistance, which is brought on by a barrier to the body's cells' ability to absorb and utilize glucose. The metabolism of lipids, proteins, and carbohydrates is hampered by this illness. Secondary pathological alterations in several organs may arise as the illness progresses, resulting in consequences such as neuropathy, nephropathy, retinopathy, and cardiovascular disorders [116].
A key factor in the development of insulin resistance is the persistent pro-inflammatory state brought on by obesity [74]. Chronic low-grade inflammation, especially in white adipose tissue, affects insulin signaling, leading to insulin resistance. Serine and threonine kinases activated by inflammatory stimuli, such as JNK, IKK, and PKC-θ, are key in this process. In obesity, these kinases are also activated by the innate immune system in response to Toll-like receptor (TLR) signals induced by microbial products such as lipopolysaccharides (LPS) and peptidoglycan [44].
One of the factors contributing to oxidative stress in type 2 diabetes is chronic inflammation [117]. Oxidative stress in metabolic problems associated with diabetes is exacerbated by increased production of advanced glycation end products [118]. Additionally, glyco-oxidation processes are triggered by oxidative stress, leading to these products' formation [119]. Research revealed that individuals with type 2 diabetes had problems with inflammation that was observed in elevated levels of TNF-α, IL-6, and CRP [120,121].
Hypoglycemia is a result of diabetes. It causes oxidative degradation, non-enzymatic protein glycation, and glucose oxidation. The primary cause of elevated free radical and reactive oxygen species levels in diabetics is hyperglycemia. This impacts the degree of antioxidant defense and causes oxidative stress and lipid peroxidation. Additional problems with glucose metabolism result from this. Type 2 diabetes and associated illnesses are facilitated by oxidative stress [122].
Numerous studies indicate the link between oxidative stress and type 2 diabetes. This connection was identified by analyzing oxidative stress biomarkers in individuals with type 2 diabetes [120,121,123,124,125,126]. Those with type 2 diabetes showed reduced glutathione peroxidase activity compared to the control group [121,123,124,126]. Jiffri et al. [121] and Mandal et al. [125] also reported decreased SOD activity, though Aouacheri et al. [123] noted an increase in this parameter, while Picu et al. [126] found no change in SOD activity. Additionally, patients with type 2 diabetes had lower levels of GSH and CAT [121,123,124,125,126], and levels of MDA, a marker of oxidative stress, were elevated in these patients [120,121,123,124,125]. Mandal et al. [125] also detected a reduced TAC. Hypoglycemia and oxidative stress can decrease the expression of CAT, SOD, and GSH-Px in pancreatic β cells, and prolonged oxidative stress can inhibit insulin secretion by these cells [127].
Using some pharmacologically active drugs or changing one's lifestyle might help prevent or postpone the onset of type 2 diabetes [115]. The onset and management of type 2 diabetes are significantly influenced by diet. It is important to prevent this illness. Certain dietary elements are very beneficial to health [128]. Studies suggest that tomato products and lycopene may be useful in the prevention and treatment of type 2 diabetes [129].
Imran et al. [130] described the antidiabetic activity of lycopene. This activity was connected with lowering blood levels of MDA, serum nitrate-nitrite, glycated hemoglobin, and CRP, downregulating the expression of RAGE receptor, NF-κB, MMP-2, and Bax proteins, increasing and enhancing the activities of antioxidant enzymes, and improving Bcl-xL and Bcl-2 levels [130].
Guo et al. [131] studied the effect of lycopene on streptozotocin-induced diabetic nephropathy in male Kunming mice. Lycopene alleviated the symptoms of nephropathy. It reduced proteinuria. Researchers observed reduced levels of fasting plasma glucose, LDL in the blood, and a decrease in urinary protein. They also noted an increase in body weight and elevated levels of HDL. In addition, lycopene showed antioxidant activity. The activities of antioxidant enzymes GPx and SOD were increased. MDA content was reduced. An immunohistochemical study showed that lycopene had anti-inflammatory effects. It was manifested as a reduction in the expression of TNF-α and NF-κB in kidney tissue. The researchers also observed increased levels of HO-1 in the kidneys. The study found that lycopene exhibits anti-inflammatory and antioxidant effects and may show protective effects in diabetic nephropathy [131]. Li et al. [132] investigated how lycopene affected renal function in diabetic nephropathy in male Sprague-Dawley rats with streptozotocin-induced diabetes. Reduced creatinine, blood urea nitrogen, and 24-hour urea protein were the results of the carotenoid. HDL rose whereas blood lipids such as TC, TG, and LDL decreased. In diabetic renal tissues, lycopene improved SOD activity, Akt/PKB phosphorylation, and reduced MDA content and CTGF expression. Through enhancing oxidative state, controlling phosphorylated Akt (p-Akt) and connective tissue growth factor (CTGF), and regulating oxidative status, lycopene prevents the development of diabetic nephropathy and improves renal function [132].
Akinnuga et al. [133] investigated the hypoglycemic effect of tomatoes containing lycopene in albino Wistar rats with streptozotocin-induced diabetes. Researchers observed a reduction in blood glucose levels after just 3 days of eating tomatoes [133]. Zhu et al. [134] investigated the effect of lycopene on oxidative stress and endothelial dysfunction in streptozotocin-induced diabetic male Wistar rats. The tested carotenoid improved endothelial function. It reduced serum glucose levels and ox-LDL levels. An increase in SOD, constitutive nitric oxide synthase (cNOS), and NO activity was also observed in the aorta. Inducible nitric oxide synthase (iNOS) activity and MDA levels in the aorta decreased. Lycopene alleviated endothelial dysfunction through its antioxidant activity [134]. In another study, scientists examined the effect of lycopene in alleviating diabetes complications in terms of its effect on angiotensin-converting enzyme activity in male Wistar-Albino male rats with streptozotocin-induced diabetes. The carotenoid caused a reduction in blood glucose and glycated hemoglobin (HbA1c) levels. It was discovered that the use of lycopene effectively inhibited angiotensin-converting enzyme (ACE) activity, a crucial marker of problems associated with diabetes [135]. In another study conducted on male Sprague-Dawley rats with streptozotocin-induced diabetes, lycopene showed antioxidant and antidiabetic effects. It lowered blood glucose levels. It reduced oxidative stress by reducing MDA levels and increasing SOD activity. The tested carotenoid also caused up-regulation of endothelial nitric oxide synthase (eNOS) expression [136]. Bayramoglu et al. [137] looked at how lycopene affected the Sprague-Dawley rats' streptozotocin-induced diabetic symptoms. The tested carotenoid had a hypoglycemic effect. It lowered glucose levels and increased serum insulin levels. It also reduced serum total cholesterol, triglyceride, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) concentrations [137]. Saad et al. [138] investigated the protective effect of lycopene on pancreatic cells in male Balb/c mice with streptozotocin-induced diabetes. The carotenoid decreased ROS levels in serum, pancreas, and liver tissues. It also decreased in CAT, SOD, and GPx. Lycopene prevented the increase in lipid peroxidation levels in the pancreas and liver [138]. Ozmen et al. [122] studied the effect of lycopene on streptozotocin-induced diabetes in Sprague-Dawley rats. The carotenoid studied did not have a negative effect on the pancreas of the test animals. It decreased vacuolization in the pancreas. The researchers observed that lycopene decreased blood and urine glucose levels. It also increased insulin levels in serum [122]. Another study evaluated the effects of lycopene on male Wistar rats with streptozotocin-induced diabetes. The researchers observed that lycopene exhibited anti-diabetic properties. It decreased blood glucose levels. The carotenoid studied also showed antioxidant activity. It increased CAT, SOD, GST, and GPx levels in the liver and decreased MDA levels in the liver. The researchers observed no significant changes in the levels of red blood cells (RBC), hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), and mean corpuscular hemoglobin (MCH). The studied carotenoid showed positive effects on the liver. It mitigated histopathological changes in this organ. It also caused an increase in AST, ALT, ALP, and LDH activities. However, no significant effect was observed on triglycerides and total cholesterol [139]. Sharma et al. [140] studied the anti-diabetic activity of lycopene niosomes in male and female Wistar rats with alloxan monohydrate-induced diabetes. The researchers observed decreased blood glucose levels. Effects on lipid profile were also noted. Total cholesterol, triglycerides, LDL, and VLDL levels were reduced [140]. In another study, researchers analyzed the effects of lycopene on changes in erythrocyte osmotic fragility and lipid peroxidation caused by streptozotocin-induced diabetes in male and female Wistar rats. The tested carotenoid significantly reduced erythrocyte osmotic fragility. It reduced the level of malondialdehyde in erythrocytes, which is an indicator of lipid peroxidation. Both observed effects were related to the antioxidant activity of lycopene [141]. Assis et al. [142] studied the effects of lycopene on streptozotocin-induced diabetic male Wistar rats. The researchers observed reduced glycemia. They also noted a reduction in serum ox-LDL and liver thiobarbituric acid reactive substances. The carotenoid increased SOD and CAT activity, as well as non-protein sulfhydryl group levels. However, no significant differences were observed in GPx levels. Lycopene lowered total cholesterol and triacylglycerol levels and increased HDL levels [142]. In another study, researchers administered lycopene to female Wistar rats with streptozotocin-induced diabetes. The tested carotenoid had an antioxidant effect. It increased the activity of SOD, CAT, GST, and GPx, and also decreased the level of MDA [143]. Malekiyan et al. [144] investigated the neuroprotective and antioxidant activity of lycopene in male Wistar rats with streptozotocin-induced diabetes. The tested carotenoid prevented apoptosis of hippocampal neurons. It also improved cognitive functions. This was related to its antioxidant activity. It increased the total antioxidant capacity (TAC) and reduced the level of MDA [144]. Yin et al. [128] investigated how lycopene affects glycolipid metabolism in male Sprague Dawley rats with streptozotocin-induced diabetes. The carotenoid reduced fasting blood glucose and the level of glycosylated hemoglobin. It increased insulin levels. It also caused a reduction in lipid levels in the liver and blood. Researchers observed increased SOD and GPx activity in the pancreas and decreased MDA levels in this organ. Lycopene had a positive effect on glycolipid metabolism and also had antidiabetic and antioxidant effects [128]. Zheng et al. [38] investigated the anti-inflammatory and antioxidant effects in male Sprague-Dawley rats with streptozotocin-induced diabetes. The tested carotenoid caused a decrease in fasting blood glucose and an increase in fasting blood insulin. It also caused a reduction in MDA, GHb, and ox-LDL levels. Researchers observed an increase in SOD, CAT, and GPx activity. There was also a noticeable reduction in inflammatory factors: CRP and TNF-α. In the study, lycopene showed antioxidant and anti-inflammatory, as well as antidiabetic effects [38].
There are also human studies on the effects of lycopene on type 2 diabetes. Table 3 summarizes those trials. A study that used 24-hour meal recalls and health checks on adult Koreans showed that non-diabetic patients consumed more lycopene than participants with diabetes [145]. However, another prospective cohort study conducted in the Netherlands found no correlation between a diet containing lycopene and the occurrence of type 2 diabetes mellitus [146]. Li et al. [147] examined serum lycopene levels in patients with type 2 diabetes mellitus who have diabetic retinopathy and those without the condition. Lycopene levels were lower in people with diabetes than in patients without the disease. Patients with diabetes and with proliferative diabetic retinopathy had lower levels of this carotenoid than those without diabetic retinopathy or with non-proliferative diabetic retinopathy. Hemoglobin A1c was negatively associated with serum lycopene concentration [147]. She et al. [148] examined the association between serum levels of carotenoids, including lycopene, and the risk of diabetes and diabetic retinopathy. However, the study found that there was no significant association between glycated hemoglobin (HbA1c) and lycopene. Serum lycopene levels were comparable in the study groups, both in healthy individuals and those with diabetes [148]. Leh et al. [149] investigated how lycopene consumption affected individuals with type 2 diabetes mellitus’ glycemic state and antioxidant capability. They observed that intake of the studied carotenoid was positively associated with peripheral antioxidant levels. An inverse relationship was observed for HbA1c and fasting plasma glucose (FPG). Their levels decreased with lycopene consumption [149].
Through the regulation of many signaling pathways, as well as its anti-inflammatory and antioxidant properties, lycopene lowers the chance of developing type 2 diabetes and has a positive impact on its treatment [92,150].
Many animal models and human studies suggest that lycopene may have beneficial effects in the context of diabetes, mainly due to its antioxidant and anti-inflammatory properties. Animal studies indicate the beneficial effect of lycopene on metabolic disorders associated with diabetes. In these studies, lycopene showed antidiabetic effects. It caused a decrease in blood glucose, LDL, total cholesterol, and triglyceride levels while increasing HDL levels. In addition, lycopene also showed a positive effect in treating diabetic nephropathy. This effect was observed through the reduction of proteinuria, creatinine, and urea nitrogen in serum. Animal studies also showed its strong antioxidant potential, which is important in the case of diabetes because, in its course, there is increased oxidative stress. Lycopene increased the activity of antioxidant enzymes such as SOD, GPx, CAT and reduced the level of MDA. The tested carotenoid also showed an anti-inflammatory effect, which also has a significant impact on inhibiting the development of metabolic diseases, such as diabetes and comorbidities. This effect was manifested by a reduction in the expression of inflammatory factors TNF-α, NF-κB, and CRP. It also improved endothelial function, reduced oxidative stress and lipid peroxidation, and protected pancreatic cells from oxidative damage. Animal studies have also indicated its neuroprotective potential. It prevented apoptosis of hippocampal neurons and improved cognitive function in diabetic animals.
In human studies, the results are less conclusive. Some studies have shown lower lycopene levels in diabetic patients, and a negative correlation between lycopene levels and HbA1c. However, other studies have not found significant associations between lycopene intake and the risk of developing type 2 diabetes mellitus, nor between lycopene levels and metabolic parameters in diabetic individuals. It may be due to methodological limitations. Further clinical studies are needed to clearly define the role of lycopene in the treatment and prevention of diabetes and its complications.
In conclusion, lycopene has shown promising antidiabetic, anti-inflammatory, and antioxidant properties in animal models, which may indicate potential benefits in the treatment of metabolic disorders associated with diabetes. However, results from human studies are mixed and require further, more detailed studies to confirm its efficacy and mechanisms of action in the context of diabetes.

5. Conclusions

Metabolic syndrome, diabetes and obesity are closely related. Their occurrence increases the risk of other health complications, including cardiovascular diseases. Obesity leads to insulin resistance, which is a key factor in the development of metabolic syndrome. Insulin resistance promotes the occurrence of metabolic dysfunctions, including elevated blood glucose levels, which can lead to the development of type 2 diabetes. On the other hand, diabetes deepens metabolic disorders and contributes to further weight gain and increased inflammation in the body. These diseases are mutually reinforcing, which means that preventing and treating one of them can have a beneficial effect on the others. Therefore, a comprehensive approach to this problem is important. Research indicates that diet and consumed ingredients have a major impact on the prevention and treatment of these diseases. Numerous studies in animal models and human trials suggest that lycopene may have beneficial effects on metabolic disorders. The conducted research provided evidence that lycopene may be a potential agent used in the prevention and treatment of metabolic syndrome, obesity and type 2 diabetes.
In the case of metabolic syndrome, animal studies have shown that lycopene alleviates symptoms such as dyslipidemia, inflammation, oxidative stress, and metabolic disorders. In human studies, lycopene administration led to improved lipid profiles, reduced inflammation, and supported metabolic functions. However, not all studies were consistent with all parameters, which may be due to methodological limitations. Therefore, further clinical trials are needed to confirm its efficacy in preventing and treating metabolic syndrome.
In the case of obesity, which often coexists with metabolic syndrome and diabetes, lycopene has shown potential to reduce inflammation, improve insulin sensitivity, and reduce fatty liver disease in animal studies. In human studies, higher blood levels of lycopene have been associated with lower BMI, waist circumference, and CRP levels, which may reduce the risk of related diseases.
Lycopene also shows promising antidiabetic properties, mainly due to its antioxidant and anti-inflammatory properties. In animal studies, lycopene lowered glucose, LDL, total cholesterol, and triglyceride levels, and increased HDL levels. Although human studies are less conclusive, lycopene may have potentially beneficial effects on diabetes. However, further clinical trials are required to confirm its effectiveness and directions of action.
In summary, lycopene has promising potential in the prevention and treatment of metabolic diseases. However, further clinical trials are needed to confirm its efficacy.

Author Contributions

Conceptualization, A.K. and P.Z.; writing—original draft preparation, A.K., J.C.-P., B.C. A.K. and P.Z .; writing—review and editing, A.K. and P.Z.; visualization, A.K. and P.Z.; supervision, P.Z..; project administration, A.K. and P.Z.; funding acquisition, A.K. and P.Z.. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Ministry of Science and Higher Education, grant number DWD/6/0002/2022.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Vona, R.; Gambardella, L.; Cittadini, C.; Straface, E.; Pietraforte, D. Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. Oxid. Med. Cell. Longev. 2019, 2019, 8267234. [Google Scholar] [CrossRef] [PubMed]
  2. Monserrat-Mesquida, M.; Quetglas-Llabrés, M.; Capó, X.; Bouzas, C.; Mateos, D.; Pons, A.; Tur, J.A.; Sureda, A. Metabolic Syndrome Is Associated with Oxidative Stress and Proinflammatory State. Antioxidants 2020, 9, 236. [Google Scholar] [CrossRef] [PubMed]
  3. Masenga, S.K.; Kabwe, L.S.; Chakulya, M.; Kirabo, A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int. J. Mol. Sci. 2023, 24, 7898. [Google Scholar] [CrossRef] [PubMed]
  4. Shi, L.; Morrison, J.A.; Wiecha, J.; Horton, M.; Hayman, L.L. Healthy Lifestyle Factors Associated with Reduced Cardiometabolic Risk. Br. J. Nutr. 2011, 105, 747–754. [Google Scholar] [CrossRef] [PubMed]
  5. Micha, R.; Peñalvo, J.L.; Cudhea, F.; Imamura, F.; Rehm, C.D.; Mozaffarian, D. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. JAMA 2017, 317, 912. [Google Scholar] [CrossRef]
  6. Manna, P.; Jain, S.K. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. Metab. Syndr. Relat. Disord. 2015, 13, 423–444. [Google Scholar] [CrossRef]
  7. Čolak, E.; Pap, D. The Role of Oxidative Stress in the Development of Obesity and Obesity-Related Metabolic Disorders. J. Med. Biochem. 2021, 40, 1–9. [Google Scholar] [CrossRef]
  8. Savini, I.; Catani, M.V.; Evangelista, D.; Gasperi, V.; Avigliano, L. Obesity-Associated Oxidative Stress: Strategies Finalized to Improve Redox State. Int. J. Mol. Sci. 2013, 14, 10497–10538. [Google Scholar] [CrossRef]
  9. Nono Nankam, P.A.; Nguelefack, T.B.; Goedecke, J.H.; Blüher, M. Contribution of Adipose Tissue Oxidative Stress to Obesity-Associated Diabetes Risk and Ethnic Differences: Focus on Women of African Ancestry. Antioxidants 2021, 10, 622. [Google Scholar] [CrossRef]
  10. Huang, C.-J.; McAllister, M.J.; Slusher, A.L.; Webb, H.E.; Mock, J.T.; Acevedo, E.O. Obesity-Related Oxidative Stress: The Impact of Physical Activity and Diet Manipulation. Sports Med. - Open 2015, 1, 32. [Google Scholar] [CrossRef]
  11. Fernández-Sánchez, A.; Madrigal-Santillán, E.; Bautista, M.; Esquivel-Soto, J.; Morales-González, Á.; Esquivel-Chirino, C.; Durante-Montiel, I.; Sánchez-Rivera, G.; Valadez-Vega, C.; Morales-González, J.A. Inflammation, Oxidative Stress, and Obesity. Int. J. Mol. Sci. 2011, 12, 3117–3132. [Google Scholar] [CrossRef] [PubMed]
  12. Pedro-Botet, J.; Ascaso, J.F.; Barrios, V.; De la Sierra, A.; Escalada, J.; Millán, J.; Mostaza, J.M.; Pérez-Martínez, P.; Pintó, X.; Salas-Salvadó, J.; et al. COSMIC Project: Consensus on the Objectives of the Metabolic Syndrome in Clinic. Diabetes Metab. Syndr. Obes. 2018, 11, 683–697. [Google Scholar] [CrossRef] [PubMed]
  13. Fahed, G.; Aoun, L.; Bou Zerdan, M.; Allam, S.; Bou Zerdan, M.; Bouferraa, Y.; Assi, H.I. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int. J. Mol. Sci. 2022, 23, 786. [Google Scholar] [CrossRef] [PubMed]
  14. Petersen, M.C.; Shulman, G.I. Mechanisms of Insulin Action and Insulin Resistance. Physiol. Rev. 2018, 98, 2133–2223. [Google Scholar] [CrossRef] [PubMed]
  15. Wolosowicz, M.; Prokopiuk, S.; Kaminski, T.W. Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle? Medicina (Mex.) 2022, 58, 472. [Google Scholar] [CrossRef]
  16. Marušić, M.; Paić, M.; Knobloch, M.; Liberati Pršo, A.-M. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can. J. Gastroenterol. Hepatol. 2021, 2021, 6613827. [Google Scholar] [CrossRef]
  17. Relevy, N.Z.; Harats, D.; Harari, A.; Ben-Amotz, A.; Bitzur, R.; Rühl, R.; Shaish, A. Vitamin A-Deficient Diet Accelerated Atherogenesis in Apolipoprotein E −/− Mice and Dietary β -Carotene Prevents This Consequence. BioMed Res. Int. 2015, 2015, 1–9. [Google Scholar] [CrossRef]
  18. Rodriguez-Concepcion, M.; Avalos, J.; Bonet, M.L.; Boronat, A.; Gomez-Gomez, L.; Hornero-Mendez, D.; Limon, M.C.; Meléndez-Martínez, A.J.; Olmedilla-Alonso, B.; Palou, A.; et al. A Global Perspective on Carotenoids: Metabolism, Biotechnology, and Benefits for Nutrition and Health. Prog. Lipid Res. 2018, 70, 62–93. [Google Scholar] [CrossRef]
  19. Wu, S.; Guo, X.; Shang, J.; Li, Y.; Dong, W.; Peng, Q.; Xie, Z.; Chen, C. Effects of Lycopene Attenuating Injuries in Ischemia and Reperfusion. Oxid. Med. Cell. Longev. 2022, 2022, 1–21. [Google Scholar] [CrossRef]
  20. Eggersdorfer, M.; Wyss, A. Carotenoids in Human Nutrition and Health. Arch. Biochem. Biophys. 2018, 652, 18–26. [Google Scholar] [CrossRef]
  21. Roust, L.R.; DiBaise, J.K. Nutrient Deficiencies Prior to Bariatric Surgery. Curr. Opin. Clin. Nutr. Metab. Care 2017, 20, 138. [Google Scholar] [CrossRef] [PubMed]
  22. Gunanti, I.R.; Marks, G.C.; Al-Mamun, A.; Long, K.Z. Low Serum Concentrations of Carotenoids and Vitamin E Are Associated with High Adiposity in Mexican-American Children1, 2. J. Nutr. 2014, 144, 489–495. [Google Scholar] [CrossRef] [PubMed]
  23. Wang, Y.-H.; Zhang, R.-R.; Yin, Y.; Tan, G.-F.; Wang, G.-L.; Liu, H.; Zhuang, J.; Zhang, J.; Zhuang, F.-Y.; Xiong, A.-S. Advances in Engineering the Production of the Natural Red Pigment Lycopene: A Systematic Review from a Biotechnology Perspective. J. Adv. Res. 2023, 46, 31–47. [Google Scholar] [CrossRef] [PubMed]
  24. Woodside, J.V.; McGrath, A.J.; Lyner, N.; McKinley, M.C. Carotenoids and Health in Older People. Maturitas 2015, 80, 63–68. [Google Scholar] [CrossRef]
  25. Kulawik, A.; Rosiak, N.; Miklaszewski, A.; Cielecka-Piontek, J.; Zalewski, P. Investigation of Cyclodextrin as Potential Carrier for Lycopene. Arch. Pharm. 2024, 74, 178–205. [Google Scholar] [CrossRef]
  26. Bin-Jumah, M.N.; Nadeem, M.S.; Gilani, S.J.; Mubeen, B.; Ullah, I.; Alzarea, S.I.; Ghoneim, M.M.; Alshehri, S.; Al-Abbasi, F.A.; Kazmi, I. Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases. Antioxidants 2022, 11, 232. [Google Scholar] [CrossRef]
  27. Wu, H.; Wu, Y.; Cui, Z.; Hu, L. Nutraceutical Delivery Systems to Improve the Bioaccessibility and Bioavailability of Lycopene: A Review. Crit. Rev. Food Sci. Nutr. 2023, 1–19. [Google Scholar] [CrossRef]
  28. Caseiro, M.; Ascenso, A.; Costa, A.; Creagh-Flynn, J.; Johnson, M.; Simões, S. Lycopene in Human Health. LWT 2020, 127, 109323. [Google Scholar] [CrossRef]
  29. Khan, U.M.; Sevindik, M.; Zarrabi, A.; Nami, M.; Ozdemir, B.; Kaplan, D.N.; Selamoglu, Z.; Hasan, M.; Kumar, M.; Alshehri, M.M.; et al. Lycopene: Food Sources, Biological Activities, and Human Health Benefits. Oxid. Med. Cell. Longev. 2021, 2021, 1–10. [Google Scholar] [CrossRef]
  30. Marzocco, S.; Singla, R.K.; Capasso, A. Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer. Molecules 2021, 26, 5333. [Google Scholar] [CrossRef]
  31. Sun, X.; Jia, H.; Xu, Q.; Zhao, C.; Xu, C. Lycopene Alleviates H 2 O 2 -Induced Oxidative Stress, Inflammation and Apoptosis in Bovine Mammary Epithelial Cells via the NFE2L2 Signaling Pathway. Food Funct. 2019, 10, 6276–6285. [Google Scholar] [CrossRef]
  32. Li, N.; Wu, X.; Zhuang, W.; Xia, L.; Chen, Y.; Wu, C.; Rao, Z.; Du, L.; Zhao, R.; Yi, M.; et al. Tomato and Lycopene and Multiple Health Outcomes: Umbrella Review. Food Chem. 2021, 343, 128396. [Google Scholar] [CrossRef] [PubMed]
  33. Landrier, J.-F.; Breniere, T.; Sani, L.; Desmarchelier, C.; Mounien, L.; Borel, P. Effect of Tomato, Tomato-Derived Products and Lycopene on Metabolic Inflammation: From Epidemiological Data to Molecular Mechanisms. Nutr. Res. Rev. 2023, 1–17. [Google Scholar] [CrossRef] [PubMed]
  34. Karakoy, Z.; Cadirci, E.; Dincer, B. A New Target in Inflammatory Diseases: Lycopene. Eurasian J. Med. 2023, 54, S23–S28. [Google Scholar] [CrossRef] [PubMed]
  35. Zhan, J.; Yan, Z.; Kong, X.; Liu, J.; Lin, Z.; Qi, W.; Wu, Y.; Lin, J.; Pan, X.; Xue, X. Lycopene Inhibits IL-1β-induced Inflammation in Mouse Chondrocytes and Mediates Murine Osteoarthritis. J. Cell. Mol. Med. 2021, 25, 3573–3584. [Google Scholar] [CrossRef]
  36. Puah, B.-P.; Jalil, J.; Attiq, A.; Kamisah, Y. New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene. Molecules 2021, 26, 3888. [Google Scholar] [CrossRef]
  37. Laranjeira, T.; Costa, A.; Faria-Silva, C.; Ribeiro, D.; de Oliveira, J.M.P.F.; Simões, S.; Ascenso, A. Sustainable Valorization of Tomato By-Products to Obtain Bioactive Compounds: Their Potential in Inflammation and Cancer Management. Molecules 2022, 27, 1701. [Google Scholar] [CrossRef]
  38. Zheng, Z.; Yin, Y.; Lu, R.; Jiang, Z. Lycopene Ameliorated Oxidative Stress and Inflammation in Type 2 Diabetic Rats. J. Food Sci. 2019, 84, 1194–1200. [Google Scholar] [CrossRef]
  39. Lee, J.; Lim, J.W.; Kim, H. Lycopene Inhibits Oxidative Stress-Mediated Inflammatory Responses in Ethanol/Palmitoleic Acid-Stimulated Pancreatic Acinar AR42J Cells. Int. J. Mol. Sci. 2021, 22, 2101. [Google Scholar] [CrossRef]
  40. Bengi V., U.; Saygun, I.; Bal, V.; Ozcan, E.; Kose Ozkan, C.; Torun, D.; Avcu, F.; Kantarcı, A. Effect of Antioxidant Lycopene on Human Osteoblasts. Clin. Oral Investig. 2022. [Google Scholar] [CrossRef]
  41. Mehta, N.; Patani, P.; Singhvi, I. A Review on Tomato Lycopene. Int. J. Pharm. Sci. Res. 2018, 9. [Google Scholar] [CrossRef]
  42. Przybylska, S. Lycopene – a Bioactive Carotenoid Offering Multiple Health Benefits: A Review. Int. J. Food Sci. Technol. 2020, 55, 11–32. [Google Scholar] [CrossRef]
  43. Wang, H.H.; Lee, D.K.; Liu, M.; Portincasa, P.; Wang, D.Q.-H. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatr. Gastroenterol. Hepatol. Nutr. 2020, 23, 189. [Google Scholar] [CrossRef] [PubMed]
  44. Lopez-Candales, A.; Hernández Burgos, P.M.; Hernandez-Suarez, D.F.; Harris, D. Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome. J. Nat. Sci. 2017, 3, e341. [Google Scholar]
  45. Bovolini, A.; Garcia, J.; Andrade, M.A.; Duarte, J.A. Metabolic Syndrome Pathophysiology and Predisposing Factors. Int. J. Sports Med. 2021, 42, 199–214. [Google Scholar] [CrossRef]
  46. Senkus, K.E.; Tan, L.; Crowe-White, K.M. Lycopene and Metabolic Syndrome: A Systematic Review of the Literature. Adv. Nutr. 2019, 10, 19–29. [Google Scholar] [CrossRef]
  47. Saklayen, M.G. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep. 2018, 20, 12. [Google Scholar] [CrossRef]
  48. Ambroselli, D.; Masciulli, F.; Romano, E.; Catanzaro, G.; Besharat, Z.M.; Massari, M.C.; Ferretti, E.; Migliaccio, S.; Izzo, L.; Ritieni, A.; et al. New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food. Nutrients 2023, 15, 640. [Google Scholar] [CrossRef]
  49. Pekgor, S.; Duran, C.; Berberoglu, U.; Eryilmaz, M.A. The Role of Visceral Adiposity Index Levels in Predicting the Presence of Metabolic Syndrome and Insulin Resistance in Overweight and Obese Patients. Metab. Syndr. Relat. Disord. 2019, 17, 296–302. [Google Scholar] [CrossRef]
  50. Matsuzawa, Y.; Funahashi, T.; Nakamura, T. The Concept of Metabolic Syndrome: Contribution of Visceral Fat Accumulation and Its Molecular Mechanism. J. Atheroscler. Thromb. 2011, 18, 629–639. [Google Scholar] [CrossRef]
  51. Fathi Dizaji, B. The Investigations of Genetic Determinants of the Metabolic Syndrome. Diabetes Metab. Syndr. Clin. Res. Rev. 2018, 12, 783–789. [Google Scholar] [CrossRef] [PubMed]
  52. Maurizi, G.; Della Guardia, L.; Maurizi, A.; Poloni, A. Adipocytes Properties and Crosstalk with Immune System in Obesity-related Inflammation. J. Cell. Physiol. 2018, 233, 88–97. [Google Scholar] [CrossRef] [PubMed]
  53. Slagter, S.N.; Van Vliet-Ostaptchouk, J.V.; Van Beek, A.P.; Keers, J.C.; Lutgers, H.L.; Van Der Klauw, M.M.; Wolffenbuttel, B.H.R. Health-Related Quality of Life in Relation to Obesity Grade, Type 2 Diabetes, Metabolic Syndrome and Inflammation. PLOS ONE 2015, 10, e0140599. [Google Scholar] [CrossRef] [PubMed]
  54. Ebron, K.; Andersen, C.J.; Aguilar, D.; Blesso, C.N.; Barona, J.; Dugan, C.E.; Jones, J.L.; Al-Sarraj, T.; Fernandez, M.L. A Larger Body Mass Index Is Associated with Increased Atherogenic Dyslipidemia, Insulin Resistance, and Low-Grade Inflammation in Individuals with Metabolic Syndrome. Metab. Syndr. Relat. Disord. 2015, 13, 458–464. [Google Scholar] [CrossRef]
  55. Marques-Rocha, J.L.; Milagro, F.I.; Mansego, M.L.; Zulet, M.A.; Bressan, J.; Martínez, J.A. Expression of Inflammation-Related miRNAs in White Blood Cells from Subjects with Metabolic Syndrome after 8 Wk of Following a Mediterranean Diet–Based Weight Loss Program. Nutrition 2016, 32, 48–55. [Google Scholar] [CrossRef]
  56. Virani, S.S.; Alonso, A.; Benjamin, E.J.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Delling, F.N.; et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation 2020, 141, e139–e596. [Google Scholar] [CrossRef]
  57. Wang, H.; Dai, Y.; Huang, S.; Rong, S.; Qi, Y.; Li, B. A New Perspective on Special Effective Interventions for Metabolic Syndrome Risk Factors: A Systematic Review and Meta-Analysis. Front. Public Health 2023, 11, 1133614. [Google Scholar] [CrossRef]
  58. Sperling, L.S.; Mechanick, J.I.; Neeland, I.J.; Herrick, C.J.; Després, J.-P.; Ndumele, C.E.; Vijayaraghavan, K.; Handelsman, Y.; Puckrein, G.A.; Araneta, M.R.G.; et al. The CardioMetabolic Health Alliance. J. Am. Coll. Cardiol. 2015, 66, 1050–1067. [Google Scholar] [CrossRef]
  59. Cai, C.; Li, H.; Zhang, L.; Li, J.; Duan, S.; Fang, Z.; Li, C.; Chen, H.; Alharbi, M.; Ye, L.; et al. Machine Learning Identification of Nutrient Intake Variations across Age Groups in Metabolic Syndrome and Healthy Populations. Nutrients 2024, 16, 1659. [Google Scholar] [CrossRef]
  60. Albrahim, T.; Alonazi, M.A. Lycopene Corrects Metabolic Syndrome and Liver Injury Induced by High Fat Diet in Obese Rats through Antioxidant, Anti-Inflammatory, Antifibrotic Pathways. Biomed. Pharmacother. 2021, 141, 111831. [Google Scholar] [CrossRef]
  61. Fenni, S.; Hammou, H.; Astier, J.; Bonnet, L.; Karkeni, E.; Couturier, C.; Tourniaire, F.; Landrier, J.-F. Lycopene and Tomato Powder Supplementation Similarly Inhibit High-Fat Diet Induced Obesity, Inflammatory Response, and Associated Metabolic Disorders. Mol. Nutr. Food Res. 2017, 61, 1601083. [Google Scholar] [CrossRef] [PubMed]
  62. Ugwor, E.I.; Ugbaja, R.N.; James, A.S.; Dosumu, O.A.; Thomas, F.C.; Ezenandu, E.O.; Graham, R.E. Inhibition of Fat Accumulation, Lipid Dysmetabolism, Cardiac Inflammation, and Improved Nitric Oxide Signalling Mediate the Protective Effects of Lycopene against Cardio-Metabolic Disorder in Obese Female Rats. Nutr. Res. 2022, 104, 140–153. [Google Scholar] [CrossRef] [PubMed]
  63. Yeo, H.Y.; Kim, O.Y.; Lim, H.H.; Kim, J.Y.; Lee, J.H. Association of Serum Lycopene and Brachial-Ankle Pulse Wave Velocity with Metabolic Syndrome. Metabolism 2011, 60, 537–543. [Google Scholar] [CrossRef] [PubMed]
  64. Liu, J.; Shi, W.; Cao, Y.; He, L.; Guan, K.; Ling, W.; Chen, Y. Higher Serum Carotenoid Concentrations Associated with a Lower Prevalence of the Metabolic Syndrome in Middle-Aged and Elderly Chinese Adults. Br. J. Nutr. 2014, 112, 2041–2048. [Google Scholar] [CrossRef] [PubMed]
  65. Han, G.-M.; Soliman, G.A.; Meza, J.L.; Islam, K.M.M.; Watanabe-Galloway, S. The Influence of BMI on the Association between Serum Lycopene and the Metabolic Syndrome. Br. J. Nutr. 2016, 115, 1292–1300. [Google Scholar] [CrossRef]
  66. Choi, J.E.; Ainsworth, B.E. Associations of Food Consumption, Serum Vitamins and Metabolic Syndrome Risk with Physical Activity Level in Middle-Aged Adults: The National Health and Nutrition Examination Survey (NHANES) 2005–2006. Public Health Nutr. 2016, 19, 1674–1683. [Google Scholar] [CrossRef]
  67. Han, G.-M.; Meza, J.L.; Soliman, G.A.; Islam, K.M.M.; Watanabe-Galloway, S. Higher Levels of Serum Lycopene Are Associated with Reduced Mortality in Individuals with Metabolic Syndrome. Nutr. Res. 2016, 36, 402–407. [Google Scholar] [CrossRef]
  68. Bouayed, J.; Vahid, F. Carotenoid Pattern Intake and Relation to Metabolic Status, Risk and Syndrome, and Its Components – Divergent Findings from the ORISCAV-LUX-2 Survey. Br. J. Nutr. 2024, 1–17. [Google Scholar] [CrossRef]
  69. Tsitsimpikou, C.; Tsarouhas, K.; Kioukia-Fougia, N.; Skondra, C.; Fragkiadaki, P.; Papalexis, P.; Stamatopoulos, P.; Kaplanis, I.; Hayes, A.W.; Tsatsakis, A.; et al. Dietary Supplementation with Tomato-Juice in Patients with Metabolic Syndrome: A Suggestion to Alleviate Detrimental Clinical Factors. Food Chem. Toxicol. 2014, 74, 9–13. [Google Scholar] [CrossRef]
  70. Li, Y.-F.; Chang, Y.-Y.; Huang, H.-C.; Wu, Y.-C.; Yang, M.-D.; Chao, P.-M. Tomato Juice Supplementation in Young Women Reduces Inflammatory Adipokine Levels Independently of Body Fat Reduction. Nutrition 2015, 31, 691–696. [Google Scholar] [CrossRef]
  71. Mirahmadi, M.; Aghasizadeh, M.; Nazifkar, F.; Ghafarian Choubdari, M.; AssaranDarban, R.; Tavallaie, S.; Hatamzadeh, H.; Ferns, G.; Mirinezhad, M.R.; Baharara, H.; et al. The Effects of Lycopene on Modulating Oxidative Stress and Liver Enzymes Levels in Metabolic Syndrome Patients: A Randomised Clinical Trial. Cell J. Yakhteh 2023, 25. [Google Scholar] [CrossRef]
  72. Lin, X.; Li, H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front. Endocrinol. 2021, 12, 706978. [Google Scholar] [CrossRef] [PubMed]
  73. Al Kibria, G.M. Prevalence and Factors Affecting Underweight, Overweight and Obesity Using Asian and World Health Organization Cutoffs among Adults in Nepal: Analysis of the Demographic and Health Survey 2016. Obes. Res. Clin. Pract. 2019, 13, 129–136. [Google Scholar] [CrossRef] [PubMed]
  74. Ahmed, B.; Sultana, R.; Greene, M.W. Adipose Tissue and Insulin Resistance in Obese. Biomed. Pharmacother. 2021, 137, 111315. [Google Scholar] [CrossRef]
  75. Chandrasekaran, P.; Weiskirchen, R. The Role of Obesity in Type 2 Diabetes Mellitus—An Overview. Int. J. Mol. Sci. 2024, 25, 1882. [Google Scholar] [CrossRef]
  76. Gregor, M.F.; Hotamisligil, G.S. Inflammatory Mechanisms in Obesity. Annu. Rev. Immunol. 2011, 29, 415–445. [Google Scholar] [CrossRef]
  77. Kivimäki, M.; Kuosma, E.; Ferrie, J.E.; Luukkonen, R.; Nyberg, S.T.; Alfredsson, L.; Batty, G.D.; Brunner, E.J.; Fransson, E.; Goldberg, M.; et al. Overweight, Obesity, and Risk of Cardiometabolic Multimorbidity: Pooled Analysis of Individual-Level Data for 120 813 Adults from 16 Cohort Studies from the USA and Europe. Lancet Public Health 2017, 2, e277–e285. [Google Scholar] [CrossRef]
  78. Liu, X.; Tang, Y.; Luo, Y.; Gao, Y.; He, L. Role and Mechanism of Specialized Pro-Resolving Mediators in Obesity-Associated Insulin Resistance. Lipids Health Dis. 2024, 23, 234. [Google Scholar] [CrossRef]
  79. Bournot, L.; Payet, T.; Sicard, F.; Breniere, T.; Astier, J.; Roux, J.; Bariohay, B.; Landrier, J.-F. Aging Alone or Combined with Obesity Increases White Adipose Tissue Inflammatory Status in Male Mice. Sci. Rep. 2024, 14, 16268. [Google Scholar] [CrossRef]
  80. Tourniaire, F.; Romier-Crouzet, B.; Lee, J.H.; Marcotorchino, J.; Gouranton, E.; Salles, J.; Malezet, C.; Astier, J.; Darmon, P.; Blouin, E.; et al. Chemokine Expression in Inflamed Adipose Tissue Is Mainly Mediated by NF-κB. PLoS ONE 2013, 8, e66515. [Google Scholar] [CrossRef]
  81. Karkeni, E.; Astier, J.; Tourniaire, F.; El Abed, M.; Romier, B.; Gouranton, E.; Wan, L.; Borel, P.; Salles, J.; Walrand, S.; et al. Obesity-Associated Inflammation Induces microRNA-155 Expression in Adipocytes and Adipose Tissue: Outcome on Adipocyte Function. J. Clin. Endocrinol. Metab. 2016, 101, 1615–1626. [Google Scholar] [CrossRef] [PubMed]
  82. Karkeni, E.; Bonnet, L.; Marcotorchino, J.; Tourniaire, F.; Astier, J.; Ye, J.; Landrier, J.-F. Vitamin D Limits Inflammation-Linked microRNA Expression in Adipocytes in Vitro and in Vivo : A New Mechanism for the Regulation of Inflammation by Vitamin D. Epigenetics 2018, 13, 156–162. [Google Scholar] [CrossRef] [PubMed]
  83. Olefsky, J.M.; Glass, C.K. Macrophages, Inflammation, and Insulin Resistance. Annu. Rev. Physiol. 2010, 72, 219–246. [Google Scholar] [CrossRef] [PubMed]
  84. Mounien, L.; Tourniaire, F.; Landrier, J.-F. Anti-Obesity Effect of Carotenoids: Direct Impact on Adipose Tissue and Adipose Tissue-Driven Indirect Effects. Nutrients 2019, 11, 1562. [Google Scholar] [CrossRef] [PubMed]
  85. Jing, Y.; Wu, F.; Li, D.; Yang, L.; Li, Q.; Li, R. Metformin Improves Obesity-Associated Inflammation by Altering Macrophages Polarization. Mol. Cell. Endocrinol. 2018, 461, 256–264. [Google Scholar] [CrossRef]
  86. Yunna, C.; Mengru, H.; Lei, W.; Weidong, C. Macrophage M1/M2 Polarization. Eur. J. Pharmacol. 2020, 877, 173090. [Google Scholar] [CrossRef]
  87. Xiao, L.; Zhang, Z.; Luo, X.; Yang, H.; Li, F.; Wang, N. Retinoid Acid Receptor-Related Orphan Receptor Alpha (RORα) Regulates Macrophage M2 Polarization via Activation of AMPKα. Mol. Immunol. 2016, 80, 17–23. [Google Scholar] [CrossRef]
  88. Zhao, L.; Kang, I.; Fang, X.; Wang, W.; Lee, M.A.; Hollins, R.R.; Marshall, M.R.; Chung, S. Gamma-Tocotrienol Attenuates High-Fat Diet-Induced Obesity and Insulin Resistance by Inhibiting Adipose Inflammation and M1 Macrophage Recruitment. Int. J. Obes. 2015, 39, 438–446. [Google Scholar] [CrossRef]
  89. Zhang, Y.; He, T.; Zhang, H. The Impact of Metabolic Disorders on Management of Periodontal Health in Children. Pediatr. Discov. 2024, 2, e38. [Google Scholar] [CrossRef]
  90. Beydoun, M.A.; Chen, X.; Jha, K.; Beydoun, H.A.; Zonderman, A.B.; Canas, J.A. Carotenoids, Vitamin A, and Their Association with the Metabolic Syndrome: A Systematic Review and Meta-Analysis. Nutr. Rev. 2019, 77, 32–45. [Google Scholar] [CrossRef]
  91. Lai, C.; Li, R.; Tang, W.; Liu, J.; Duan, X.; Bao, D.; Liu, H.; Fu, S. Metabolic Syndrome and Tendon Disease: A Comprehensive Review. Diabetes Metab. Syndr. Obes. 2024, Volume 17, 1597–1609. [Google Scholar] [CrossRef]
  92. Zhu, R.; Chen, B.; Bai, Y.; Miao, T.; Rui, L.; Zhang, H.; Xia, B.; Li, Y.; Gao, S.; Wang, X.-D.; et al. Lycopene in Protection against Obesity and Diabetes: A Mechanistic Review. Pharmacol. Res. 2020, 159, 104966. [Google Scholar] [CrossRef] [PubMed]
  93. Marcotorchino, J.; Romier, B.; Gouranton, E.; Riollet, C.; Gleize, B.; Malezet-Desmoulins, C.; Landrier, J.-F. Lycopene Attenuates LPS-Induced TNF-α Secretion in Macrophages and Inflammatory Markers in Adipocytes Exposed to Macrophage-Conditioned Media. Mol. Nutr. Food Res. 2012, 56, 725–732. [Google Scholar] [CrossRef]
  94. Gouranton, E.; Thabuis, C.; Riollet, C.; Malezet-Desmoulins, C.; El Yazidi, C.; Amiot, M.J.; Borel, P.; Landrier, J.F. Lycopene Inhibits Proinflammatory Cytokine and Chemokine Expression in Adipose Tissue. J. Nutr. Biochem. 2011, 22, 642–648. [Google Scholar] [CrossRef] [PubMed]
  95. Bahcecioglu, I.H.; Kuzu, N.; Metin, K.; Ozercan, I.H.; Ustündag, B.; Sahin, K.; Kucuk, O. Lycopene Prevents Development of Steatohepatitis in Experimental Nonalcoholic Steatohepatitis Model Induced by High-Fat Diet. Vet. Med. Int. 2010, 2010, 1–8. [Google Scholar] [CrossRef]
  96. Chen, G.; Ni, Y.; Nagata, N.; Zhuge, F.; Xu, L.; Nagashimada, M.; Yamamoto, S.; Ushida, Y.; Fuke, N.; Suganuma, H.; et al. Lycopene Alleviates Obesity-Induced Inflammation and Insulin Resistance by Regulating M1/M2 Status of Macrophages. Mol. Nutr. Food Res. 2019, 63, 1900602. [Google Scholar] [CrossRef]
  97. Singh, D.P.; Khare, P.; Zhu, J.; Kondepudi, K.K.; Singh, J.; Baboota, R.K.; Boparai, R.K.; Khardori, R.; Chopra, K.; Bishnoi, M. A Novel Cobiotic-Based Preventive Approach against High-Fat Diet-Induced Adiposity, Nonalcoholic Fatty Liver and Gut Derangement in Mice. Int. J. Obes. 2016, 40, 487–496. [Google Scholar] [CrossRef]
  98. Kim, A.-Y.; Jeong, Y.-J.; Park, Y.B.; Lee, M.-K.; Jeon, S.-M.; McGregor, R.A.; Choi, M.-S. Dose Dependent Effects of Lycopene Enriched Tomato-Wine on Liver and Adipose Tissue in High-Fat Diet Fed Rats. Food Chem. 2012, 130, 42–48. [Google Scholar] [CrossRef]
  99. Wang, J.; Suo, Y.; Zhang, J.; Zou, Q.; Tan, X.; Yuan, T.; Liu, Z.; Liu, X. Lycopene Supplementation Attenuates Western Diet-Induced Body Weight Gain through Increasing the Expressions of Thermogenic/Mitochondrial Functional Genes and Improving Insulin Resistance in the Adipose Tissue of Obese Mice. J. Nutr. Biochem. 2019, 69, 63–72. [Google Scholar] [CrossRef]
  100. Zeng, Z.; He, W.; Jia, Z.; Hao, S. Lycopene Improves Insulin Sensitivity through Inhibition of STAT3/Srebp-1c-Mediated Lipid Accumulation and Inflammation in Mice Fed a High-Fat Diet. Exp. Clin. Endocrinol. Diabetes 2017, 125, 610–617. [Google Scholar] [CrossRef]
  101. Lorenz, M.; Fechner, M.; Kalkowski, J.; Fröhlich, K.; Trautmann, A.; Böhm, V.; Liebisch, G.; Lehneis, S.; Schmitz, G.; Ludwig, A.; et al. Effects of Lycopene on the Initial State of Atherosclerosis in New Zealand White (NZW) Rabbits. PLoS ONE 2012, 7, e30808. [Google Scholar] [CrossRef] [PubMed]
  102. Luvizotto, R.D.A.M.; Nascimento, A.F.; Imaizumi, E.; Pierine, D.T.; Conde, S.J.; Correa, C.R.; Yeum, K.-J.; Ferreira, A.L.A. Lycopene Supplementation Modulates Plasma Concentrations and Epididymal Adipose Tissue mRNA of Leptin, Resistin and IL-6 in Diet-Induced Obese Rats. Br. J. Nutr. 2013, 110, 1803–1809. [Google Scholar] [CrossRef] [PubMed]
  103. Luvizotto, R.; Nascimento, A.; Miranda, N.; Wang, X.-D.; Ferreira, A. Lycopene-Rich Tomato Oleoresin Modulates Plasma Adiponectin Concentration and mRNA Levels of Adiponectin, SIRT1, and FoxO1 in Adipose Tissue of Obese Rats. Hum. Exp. Toxicol. 2015, 34, 612–619. [Google Scholar] [CrossRef] [PubMed]
  104. Wang, Y.; Ausman, L.M.; Greenberg, A.S.; Russell, R.M.; Wang, X. Dietary Lycopene and Tomato Extract Supplementations Inhibit Nonalcoholic Steatohepatitis-promoted Hepatocarcinogenesis in Rats. Int. J. Cancer 2010, 126, 1788–1796. [Google Scholar] [CrossRef]
  105. Pierine, D.T.; Navarro, M.E.L.; Minatel, I.O.; Luvizotto, R.A.M.; Nascimento, A.F.; Ferreira, A.L.A.; Yeum, K.-J.; Corrêa, C.R. Lycopene Supplementation Reduces TNF-α via RAGE in the Kidney of Obese Rats. Nutr. Diabetes 2014, 4, e142–e142. [Google Scholar] [CrossRef]
  106. Harari, A.; Coster, A.C.; Jenkins, A.; Xu, A.; Greenfield, J.R.; Harats, D.; Shaish, A.; Samocha-Bonet, D. Obesity and Insulin Resistance Are Inversely Associated with Serum and Adipose Tissue Carotenoid Concentrations in Adults. J. Nutr. 2020, 150, 38–46. [Google Scholar] [CrossRef]
  107. Han, G.-M.; Liu, P. Higher Serum Lycopene Is Associated with Reduced Prevalence of Hypertension in Overweight or Obese Adults. Eur. J. Integr. Med. 2017, 13, 34–40. [Google Scholar] [CrossRef]
  108. McMorrow, A.M.; Connaughton, R.M.; Magalhães, T.R.; McGillicuddy, F.C.; Hughes, M.F.; Cheishvili, D.; Morine, M.J.; Ennis, S.; Healy, M.; Roche, E.F.; et al. Personalized Cardio-Metabolic Responses to an Anti-Inflammatory Nutrition Intervention in Obese Adolescents: A Randomized Controlled Crossover Trial. Mol. Nutr. Food Res. 2018, 62, 1701008. [Google Scholar] [CrossRef]
  109. Negri, R.; Trinchese, G.; Carbone, F.; Caprio, M.G.; Stanzione, G.; Di Scala, C.; Micillo, T.; Perna, F.; Tarotto, L.; Gelzo, M.; et al. Randomised Clinical Trial: Calorie Restriction Regimen with Tomato Juice Supplementation Ameliorates Oxidative Stress and Preserves a Proper Immune Surveillance Modulating Mitochondrial Bioenergetics of T-Lymphocytes in Obese Children Affected by Non-Alcoholic Fatty Liver Disease (NAFLD). J. Clin. Med. 2020, 9, 141. [Google Scholar] [CrossRef]
  110. Park, E. Birth Weight Was Negatively Correlated with Plasma Ghrelin, Insulin Resistance, and Coenzyme Q10 Levels in Overweight Children. Nutr. Res. Pract. 2010, 4, 311. [Google Scholar] [CrossRef]
  111. Ghavipour, M.; Sotoudeh, G.; Ghorbani, M. Tomato Juice Consumption Improves Blood Antioxidative Biomarkers in Overweight and Obese Females. Clin. Nutr. 2015, 34, 805–809. [Google Scholar] [CrossRef] [PubMed]
  112. Wiese, M.; Bashmakov, Y.; Chalyk, N.; Nielsen, D.S.; Krych, Ł.; Kot, W.; Klochkov, V.; Pristensky, D.; Bandaletova, T.; Chernyshova, M.; et al. Prebiotic Effect of Lycopene and Dark Chocolate on Gut Microbiome with Systemic Changes in Liver Metabolism, Skeletal Muscles and Skin in Moderately Obese Persons. BioMed Res. Int. 2019, 2019, 1–15. [Google Scholar] [CrossRef] [PubMed]
  113. Ben Amara, N.; Tourniaire, F.; Maraninchi, M.; Attia, N.; Amiot-Carlin, M.J.; Raccah, D.; Valéro, R.; Landrier, J.F.; Darmon, P. Independent Positive Association of Plasma β-Carotene Concentrations with Adiponectin among Non-Diabetic Obese Subjects. Eur. J. Nutr. 2015, 54, 447–454. [Google Scholar] [CrossRef] [PubMed]
  114. Lin, X.; Xu, Y.; Pan, X.; Xu, J.; Ding, Y.; Sun, X.; Song, X.; Ren, Y.; Shan, P.-F. Global, Regional, and National Burden and Trend of Diabetes in 195 Countries and Territories: An Analysis from 1990 to 2025. Sci. Rep. 2020, 10, 14790. [Google Scholar] [CrossRef]
  115. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Res. Clin. Pract. 2019, 157, 107843. [Google Scholar] [CrossRef]
  116. Ansari, P.; Akther, S.; Hannan, J.M.A.; Seidel, V.; Nujat, N.J.; Abdel-Wahab, Y.H.A. Pharmacologically Active Phytomolecules Isolated from Traditional Antidiabetic Plants and Their Therapeutic Role for the Management of Diabetes Mellitus. Molecules 2022, 27, 4278. [Google Scholar] [CrossRef]
  117. Bhatti, J.S.; Sehrawat, A.; Mishra, J.; Sidhu, I.S.; Navik, U.; Khullar, N.; Kumar, S.; Bhatti, G.K.; Reddy, P.H. Oxidative Stress in the Pathophysiology of Type 2 Diabetes and Related Complications: Current Therapeutics Strategies and Future Perspectives. Free Radic. Biol. Med. 2022, 184, 114–134. [Google Scholar] [CrossRef]
  118. Ruiz, H.H.; Ramasamy, R.; Schmidt, A.M. Advanced Glycation End Products: Building on the Concept of the “Common Soil” in Metabolic Disease. Endocrinology 2020, 161, bqz006. [Google Scholar] [CrossRef]
  119. Moldogazieva, N.T.; Mokhosoev, I.M.; Mel’nikova, T.I.; Porozov, Y.B.; Terentiev, A.A. Oxidative Stress and Advanced Lipoxidation and Glycation End Products (ALEs and AGEs) in Aging and Age-Related Diseases. Oxid. Med. Cell. Longev. 2019, 2019, 1–14. [Google Scholar] [CrossRef]
  120. Casoinic, F.; Sampelean, D.; Buzoianu, A.D.; Hancu, N.; Baston, D. Serum Levels of Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis. Rom. J. Intern. Med. 2016, 54, 228–236. [Google Scholar] [CrossRef]
  121. Al-Jiffri, E.H. Association between Adipocytokines, Systemic Inflammation and Oxidative Stress Biomarkers among Obese Type 2 Diabetic Patients. Adv. Res. Gastroenterol. Hepatol. 2017, 5. [Google Scholar] [CrossRef]
  122. Ozmen, O.; Topsakal, S.; Haligur, M.; Aydogan, A.; Dincoglu, D. Effects of Caffeine and Lycopene in Experimentally Induced Diabetes Mellitus. Pancreas 2016, 45, 579–583. [Google Scholar] [CrossRef] [PubMed]
  123. Aouacheri, O.; Saka, S.; Krim, M.; Messaadia, A.; Maidi, I. The Investigation of the Oxidative Stress-Related Parameters in Type 2 Diabetes Mellitus. Can. J. Diabetes 2015, 39, 44–49. [Google Scholar] [CrossRef] [PubMed]
  124. Lasisi, I.A.; Adedokun, K.A.; Oyenike, M.A.; Muhibi, M.A.; Kamorudeen, R.T.; Oluogun, W.A. Glycemic Control and Its Impact on Oxidative Stress Biomarkers in Type 2 Diabetic Patients Treated with Metformin: A Cross-Sectional Analysis. Sci. Medica 2019, 29, 33630. [Google Scholar] [CrossRef]
  125. Mandal, M.; Varghese, A.; Gaviraju, V.K.; Talwar, S.N.; Malini, S.S. Impact of Hyperglycaemia on Molecular Markers of Oxidative Stress and Antioxidants in Type 2 Diabetes Mellitus. Clin. Diabetol. 2019, 8, 215–222. [Google Scholar] [CrossRef]
  126. Picu, A.; Petcu, L.; Ştefan, S.; Mitu, M.; Lixandru, D.; Ionescu-Tîrgovişte, C.; Pîrcălăbioru, G.G.; Ciulu-Costinescu, F.; Bubulica, M.-V.; Chifiriuc, M.C. Markers of Oxidative Stress and Antioxidant Defense in Romanian Patients with Type 2 Diabetes Mellitus and Obesity. Molecules 2017, 22, 714. [Google Scholar] [CrossRef]
  127. Zhang, P.; Li, T.; Wu, X.; Nice, E.C.; Huang, C.; Zhang, Y. Oxidative Stress and Diabetes: Antioxidative Strategies. Front. Med. 2020, 14, 583–600. [Google Scholar] [CrossRef]
  128. Yin, Y.; Zheng, Z.; Jiang, Z. Effects of Lycopene on Metabolism of Glycolipid in Type 2 Diabetic Rats. Biomed. Pharmacother. 2019, 109, 2070–2077. [Google Scholar] [CrossRef]
  129. Kulawik, A.; Cielecka-Piontek, J.; Zalewski, P. The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene. Nutrients 2023, 15, 3821. [Google Scholar] [CrossRef]
  130. Imran, M.; Ghorat, F.; Ul-Haq, I.; Ur-Rehman, H.; Aslam, F.; Heydari, M.; Shariati, M.A.; Okuskhanova, E.; Yessimbekov, Z.; Thiruvengadam, M.; et al. Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders. Antioxidants 2020, 9, 706. [Google Scholar] [CrossRef]
  131. Guo, Y.; Liu, Y.; Wang, Y. Beneficial Effect of Lycopene on Anti-Diabetic Nephropathy through Diminishing Inflammatory Response and Oxidative Stress. Food Funct. 2015, 6, 1150–1156. [Google Scholar] [CrossRef] [PubMed]
  132. Li, W.; Wang, G.; Lu, X.; Jiang, Y.; Xu, L.; Zhao, X. Lycopene Ameliorates Renal Function in Rats with Streptozotocin-Induced Diabetes. Int. J. Clin. Exp. Pathol. 2014, 7, 5008–5015. [Google Scholar] [PubMed]
  133. Akinnuga Hypoglycaemic Effects of Dietary Intake of Ripe and Unripe Lycopersicon Esculentum (Tomatoes) on Streptozotocin-Induced Diabetes Mellitus in Rats. OnLine J. Biol. Sci. 2010, 10, 50–53. [CrossRef]
  134. Zhu, J.; Wang, C.; Xu, Y. Lycopene Attenuates Endothelial Dysfunction in Streptozotocin-Induced Diabetic Rats by Reducing Oxidative Stress. Pharm. Biol. 2011, 49, 1144–1149. [Google Scholar] [CrossRef]
  135. Ozmutlu, S.; Dede, S.; Ceylan, E. The Effect of Lycopene Treatment on ACE Activity in Rats with Experimental Diabetes. J. Renin Angiotensin Aldosterone Syst. 2012, 13, 328–333. [Google Scholar] [CrossRef]
  136. Gao, J.-X.; Li, Y.; He, X.-L.; Bai, A.-S. Lycopene Ameliorates Erectile Dysfunction in Streptozotocin-Induced Diabetic Rats. Pharmazie 2012, 256–259. [Google Scholar] [CrossRef]
  137. Bayramoglu, A.; Bayramoglu, G.; Senturk, H. Lycopene Partially Reverses Symptoms of Diabetes in Rats with Streptozotocin-Induced Diabetes. J. Med. Food 2013, 16, 128–132. [Google Scholar] [CrossRef]
  138. Saad, A.; Ahmad, W. The Role of Lycopene from Zizyphus Spina-Christi in the Prevention of Streptozotocin-Induced Diabetes Mellitus in Balb/C Mice. Middle-East J. Sci. Res. 2013, 16, 952–956. [Google Scholar] [CrossRef]
  139. Baş, H.; Pandır, D.; Kalender, S. Furan-Induced Hepatotoxic and Hematologic Changes in Diabetic Rats: The Protective Role of Lycopene. Arch. Ind. Hyg. Toxicol. 2016, 67, 194–203. [Google Scholar] [CrossRef]
  140. Sharma, P.; Saxena, P.; Jaswanth, A.; Chalamaiah, M.; Balasubramaniam, A. Anti-Diabetic Activity of Lycopene Niosomes: Experimental Observation. J. Pharm. Drug Dev. 2017, 4, 1. [Google Scholar] [CrossRef]
  141. Eze, E.D.; Tanko, Y.; Abubakar, A.; Sulaiman, S.O.; Rabiu, K.M.; Mohammed, A. Lycopene Ameliorates Diabetic-Induced Changes in Erythrocyte Osmotic Fragility and Lipid Peroxidation in Wistar Rats. J. Diabetes Mellit. 2017, 07, 71–85. [Google Scholar] [CrossRef]
  142. Assis, R.; Arcaro, C.; Gutierres, V.; Oliveira, J.; Costa, P.; Baviera, A.; Brunetti, I. Combined Effects of Curcumin and Lycopene or Bixin in Yoghurt on Inhibition of LDL Oxidation and Increases in HDL and Paraoxonase Levels in Streptozotocin-Diabetic Rats. Int. J. Mol. Sci. 2017, 18, 332. [Google Scholar] [CrossRef] [PubMed]
  143. Uçar, S.; Pandir, D. Furan Induced Ovarian Damage in Non-Diabetic and Diabetic Rats and Cellular Protective Role of Lycopene. Arch. Gynecol. Obstet. 2017, 296, 1027–1037. [Google Scholar] [CrossRef] [PubMed]
  144. Malekiyan, R.; Abdanipour, A.; Sohrabi, D.; Jafari Anarkooli, I. Antioxidant and Neuroprotective Effects of Lycopene and Insulin in the Hippocampus of Streptozotocin-induced Diabetic Rats. Biomed. Rep. 2018. [Google Scholar] [CrossRef]
  145. Quansah, D.; Ha, K.; Jun, S.; Kim, S.-A.; Shin, S.; Wie, G.-A.; Joung, H. Associations of Dietary Antioxidants and Risk of Type 2 Diabetes: Data from the 2007–2012 Korea National Health and Nutrition Examination Survey. Molecules 2017, 22, 1664. [Google Scholar] [CrossRef]
  146. Sluijs, I.; Cadier, E.; Beulens, J.W.J.; van der A, D.L.; Spijkerman, A.M.W.; van der Schouw, Y.T. Dietary Intake of Carotenoids and Risk of Type 2 Diabetes. Nutr. Metab. Cardiovasc. Dis. 2015, 25, 376–381. [Google Scholar] [CrossRef]
  147. Li, Z.-Z.; Lu, X.-Z.; Ma, C.-C.; Chen, L. Serum Lycopene Levels in Patients with Diabetic Retinopathy. Eur. J. Ophthalmol. 2010, 20, 719–723. [Google Scholar] [CrossRef]
  148. She, C.; Shang, F.; Zhou, K.; Liu, N. Serum Carotenoids and Risks of Diabetes and Diabetic Retinopathy in a Chinese Population Sample. Curr. Mol. Med. 2017, 17. [Google Scholar] [CrossRef]
  149. Leh, H.E.; Mohd Sopian, M.; Abu Bakar, M.H.; Lee, L.K. The Role of Lycopene for the Amelioration of Glycaemic Status and Peripheral Antioxidant Capacity among the Type II Diabetes Mellitus Patients: A Case–Control Study. Ann. Med. 2021, 53, 1060–1066. [Google Scholar] [CrossRef]
  150. Motta, B.P.; Pinheiro, C.G.; Figueiredo, I.D.; Cardoso, F.N.; Oliveira, J.O.; Machado, R.T.A.; da Silva, P.B.; Chorilli, M.; Brunetti, I.L.; Baviera, A.M. Combined Effects of Lycopene and Metformin on Decreasing Oxidative Stress by Triggering Endogenous Antioxidant Defenses in Diet-Induced Obese Mice. Molecules 2022, 27, 8503. [Google Scholar] [CrossRef]
Table 1. Human studies evaluating lycopene's impact on metabolic syndrome.
Table 1. Human studies evaluating lycopene's impact on metabolic syndrome.
Participants Study type MetS definition Lycopene dosage Main results Year Reference
299 Korean men,
48-50 years		 Cross-sectional study modified ATP III guidelines, American Diabetes Association guidelines, and Asian-Pacific guidelines Dietary intake 1. Lycopene levels decreased with increasing MetS risk factors. 2011 [63]
2. Higher brachial-ankle pulse wave velocity in MetS may be associated with lower lycopene levels.
2,148 participants from China (1,547 women and 601 men), 50-75 years Cross-sectional study 2005 International Diabetes Federation MetS diagnostic criteria Dietary intake 1. People with MetS had higher waist circumference, BMI, blood pressure, fasting blood glucose, triglycerides, and lower HDL. 2014 [64]
2. People without MetS had higher α-tocopherol and retinol levels.
3. Serum carotenoid concentrations were inversely related to MetS incidence.
13,196 participants (6,335 men and 6,861 women), 20 years or older Cross-sectional study ATP III criteria Dietary intake 1. Participants with the lowest lycopene concentrations had a higher incidence of MetS than those with higher lycopene levels. 2016 [65]
2. BMI influenced the link between serum lycopene levels and MetS incidence (significant in overweight and normal-weight people, not in obese people).
1,930 participants (948 men and 982 women), 40-70 years Cross-sectional study ATP III criteria Dietary intake 1. Translycopene concentrations were positively related to the daily number of steps. 2016 [66]
2. People with sedentary lifestyles had a higher risk of developing MetS.
3. Elevated blood levels of carotenoids, especially lycopene, are probably linked to a lower risk of MetS and an increased number of steps.
2,499 participants with metabolic syndrome (1,209 men and 1,290 women), 20 years or older Cross-sectional study ATP III criteria Dietary intake 1. People with metabolic syndrome and the highest lycopene levels had longer average survival times than those with the lowest levels. 2016 [67]
1,346 participants (630 men and 716 women), 25–79 years Cross-sectional study ATP III criteria Dietary intake 1. Carotenoid intake varied impact on metabolic state, risk, and MetS components. 2024 [68]
2. Lycopene showed favorable correlation with MetS scores.
Tomato juice group: 13 men and 2 women,
control group: 11 men and 1 woman, participants with metabolic syndrome, 43-67 years		 Comparative study American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) definition Once a day unspecified amount of tomato juice containing 2.51 mg of lycopene in 100 ml, four times a week or a placebo for 2 months 1. Increased HDL, 2014 [69]
2. Decreased LDL,
3. Reduced fasting insulin resistance score,
4. Reduced inflammation,
5. Reduced endothelial dysfunction
25 women, BMI ≥20, 20–30 years, no control group Cross-sectional, single-center study Not reported 280 ml tomato
juice daily, containing 32.5 mg of lycopene for 2 months		 1. Decreased cholesterol, 2015 [70]
2. Decreased thiobarbituric reactive chemicals,
3. Decreased MCP-1,
4. Decreased body weight, body fat, waist circumference and BMI,
5. Increased triglycerides,
6. Increased lycopene level,
7. Increased adiponectin
Lycopene group: 18 men and 22 women, control group: 12 men and 28 women,
participants with metabolic syndrome, 18-60 years		 Randomized, double-blind, objective-based clinical trial International Diabetes Federation criteria 20 mg of lycopene per day or a placebo for 8 weeks 1. Decreased CRP, 2023 [71]
2. Decreased PAB,
3. No differences in ALT, AST, and ALP levels
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate transferase; ATP III: National Cholesterol Education Program’s Adult Treatment Panel III; BMI: body mass index; CRP: C-reactive protein; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; MCP-1: monocyte chemoattractant protein-1; MetS: metabolic syndrome; PAB: prooxidant-antioxidant balance.
Table 2. Human studies evaluating lycopene's impact on obesity.
Table 2. Human studies evaluating lycopene's impact on obesity.
Participants Study type Lycopene dosage Main results Year Reference
80 participants (31 men and 49 women), BMI: 30.1-48.5, 18–70 years Small cohort, cross-sectional analysis Dietary intake 1. Lycopene concentration lower in people with obesity. 2020 [106]
8,556 participants (4,266 men and 4,296 women), BMI ≥ 25, 20 years and older Cross-sectional study Dietary intake 1. Blood lycopene levels inversely associated with hypertension, 2017 [107]
2. The lycopene to uric acid ratio significantly associated with hypertension in overweight and obese individuals.
70 overweight adolescents, BMI > 31, 13-18 years Randomized double-blind, placebo-controlled, crossover trial Dietary supplement including, among others, lycopene, for 8 weeks 1. Preserved high molecular weight adiponectin levels, 2018 [108]
2. Decreased insulin resistance.
52 obese children with fatty liver, BMI > 85th percentile, 4–14 years Randomized, crossover, double-blind trial 100 ml of lycopene-enriched (0.011 %) tomato juice daily for 60 days 1. Enhanced lipid and glucose metabolism, 2020 [109]
2. Reduced inflammation and oxidative stress,
3. Impact on T lymphocyte mitochondrial metabolic control.
34 overweight children (18 boys and 16 girls), BMI > 21, 9-10 years Observational study Dietary intake 1. Serum lycopene levels are negatively correlated with BMI. 2010 [110]
64 women, BMI ≥ 25, 20-30 years Randomized controlled clinical trial 330 ml tomato
juice daily, containing 37.0 mg of lycopene or water (placebo) for 20 days		 1. In overweight people: increased TAC, SOD, GPx, and CAT, decreased MDA, 2015 [111]
2. In obese people: these changes were not statistically significant.
30 participants (15 men and 15 women), BMI: 30-35, 40-68 years Randomized, double-blind trial 7 or 30 mg lycopene daily in different formulations or placebo for 1 month 1. Enhanced the relative number of beneficial gut microorganisms, 2019 [112]
2. Improved skeletal muscle oxygenation and hepatic lipid metabolism,
3. Decreased in skin corneocyte desquamation,
4. Increased skin sebum viscosity.
108 obese, non-diabetic participants (26 men and 82 women), BMI ≥ 30, 18-70 years Cross-sectional study Dietary intake 1. No correlation between plasma lycopene levels and BMI, adipokines, or insulin resistance. 2015 [113]
CAT: catalase; BMI: body mass index; GPx: glutathione peroxidase; MDA: malondialdehyde; SOD: superoxide dismutase; TAC: total antioxidant capacity.
Table 3. Human studies evaluating lycopene's impact on diabetes mellitus.
Table 3. Human studies evaluating lycopene's impact on diabetes mellitus.
Participants Study type Lycopene dosage Main results Year Reference
37,846 participants (men and women) from Utrecht and its surroundings, Amsterdam, Doetinchem, and Maastricht, Netherlands Prospective cohort study Dietary intake 1. No correlation between a diet containing lycopene and the occurrence of type 2 diabetes. 2014 [146]
24,377 Korean adults (9,779 men and 14,598 women), including 603 people with T2DM (332 men and 271 women) Cross-sectional surveillance Dietary intake 1. Non-diabetic patients consumed more lycopene than diabetic patients. 2017 [145]
T2DM group: 71 patients, control group: 23 patients Case-control study Dietary intake 1. HbA1c negatively associated with serum lycopene concentration, 2010 [147]
2. Lower lycopene levels in people with diabetes than without,
3. Lower lycopene levels in diabetic patients with proliferative diabetic retinopathy than those without retinopathy,
4. Lower lycopene levels in proliferative diabetic retinopathy compared to non-proliferative
Diabetic retinopathy group: 272 patients, diabetes mellitus without retinopathy group: 190 patients, control group: 285 patients Cross-sectional study Dietary intake 1. No significant relationship between HbA1c levels and lycopene 2017 [148]
T2DM group: 87 patients, control group: 122 patients Case-control study Dietary intake, 0.04 mg/kg/day for 12 months 1. Fasting plasma glucose and HbA1c levels significantly decreased with increased lycopene consumption 2021 [149]
HbA1c: glycated hemoglobin; T2DM: type II diabetes mellitus.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated